This is **Exhibit "F"** referred to in the Affidavit of **TODD CAIN**Affirmed before me at the City of Ottawa, in the Province of Ontario, this 15th day of January 2015.

A Commissioner for Taking Affidavits

Sherri Laureen Szabados, a Commissioner, etc., Province of Ontario, for the Government of Canada, Department of Health, Expires December 2, 2015

DEPARTMENT OF FISHERIES AND OCEANS

FISHERIES ACT

Notice of intent with respect to amending the Pacific Aquaculture Regulations to include Aquaculture Licence Fees

Fisheries and Oceans Canada intends to charge licence fees for all federally licensed aquaculture operations in British Columbia, with the exception of non-commercial production facilities including not-for-profit, salmon enhancement, and universities. The licence fee will be implemented through an amendment to the Pacific Aquaculture Regulations. This process is also subject to the provisions of the User Fees Act, which requires that the fee proposal be tabled in Parliament before it is finalized.

A discussion paper summarizing the proposed fee structure, service standards, consultations to date, and the anticipated impacts of the proposal will be posted on the Department's Web site. All affected and interested parties are invited to review the discussion paper, and participate fully during the comment period of the consultation process which will begin on December 17, 2012, and conclude on January 16, 2013.

For further information, please consult the Department's Web site at www.dfo-mpo.gc.ca/aquaculture/aquaculture-eng.htm.

December 15, 2012

AQUACULTURE MANAGEMENT DIRECTORATE

[50-1-0]

MINISTÈRE DES PÊCHES ET DES OCÉANS

LOI SUR LES PÊCHES

Avis d'intention concernant la modification du Règlement du Pacifique sur l'aquaculture afin d'y ajouter les droits de permis d'aquaculture

Pêches et Océans Canada a l'intention d'imposer des droits de permis à toutes les activités d'aquaculture réglementées par le gouvernement fédéral en Colombie-Britannique, sauf dans le cas des installations de production non commerciales telles que les établissements à but non lucratif, les organismes de mise en valeur du saumon et les universités. Les droits de permis seront officialisés par l'entremise de la modification du Règlement du Pacifique sur l'aquaculture. Cette mesure est assujettie aux dispositions de la Loi sur les frais d'utilisation, qui exigent le dépôt au Parlement des droits proposés avant d'être finalisée.

Un document de travail résumant le barème de droits proposé, les normes de service, les activités de consultation menées jusqu'à présent et les incidences prévues de la mesure sera également affiché sur le site Web du Ministère. On invite toutes les parties intéressées à examiner le document de travail et à s'exprimer librement pendant la période des commentaires du processus de consultation qui se déroulera du 17 décembre 2012 au 16 janvier 2013.

Pour de plus amples renseignements, veuillez consulter le site Web du Ministère au www.dfo-mpo.gc.ca/aquaculture/aquaculture-fra.htm.

Le 15 décembre 2012

LA DIRECTION GÉNÉRALE DE LA GESTION DE L'AQUACULTURE

[50-1-o]

DEPARTMENT OF HEALTH

CONTROLLED DRUGS AND SUBSTANCES ACT

Notice to interested parties — Proposed improvements to the Marihuana Medical Access Program (MMAP) — Research and development activities

On December 15, 2012, Health Canada is publishing the proposed Marihuana for Medical Purposes Regulations (MMPR) in the Canada Gazette, Part I. The proposed Regulations can be found at www.gazette.gc.ca/rp-pr/p1/2012/2012-12-15/html/reg4-eng.html.

The proposed Regulations would establish the conditions for a competitive industry of licensed producers, which would offer individuals access to dried marihuana for medical purposes, produced under secure and sanitary conditions. A licensed producer (LP) would have to meet regulatory requirements for elements such as quality control standards and security measures. This would reduce risks to public health, safety and security resulting from such production. After the new Regulations come into force, interested persons would be able to apply for a licence and, if they qualify, immediately begin producing and distributing dried marihuana for medical purposes.

Parties who are considering becoming an LP and are interested in engaging in certain research and development activities such as testing marihuana or testing growing conditions on-site may do so prior to the MMPR coming into force using existing mechanisms

MINISTÈRE DE LA SANTÉ

LOI RÉGLEMENTANT CERTAINES DROGUES ET AUTRES SUBSTANCES

Avis aux parties intéressées — Améliorations proposées aux activités de recherche et de développement du Programme d'accès à la marihuana à des fins médicales (PAMFM)

Le 15 décembre 2012, Santé Canada publie le Règlement sur l'accès à la marihuana à des fins médicales (RAMFM) proposé dans la Partie I de la Gazette du Canada. Le projet de règlement se trouve au www.gazette.gc.ca/rp-pr/p1/2012/2012-12-15/html/reg4-fra.html.

Le projet de règlement établit les conditions pour une industrie concurrentielle de producteurs autorisés, ce qui permettrait aux individus d'obtenir de la marihuana séchée à des fins médicales produite dans des conditions sanitaires et sécuritaires. Les producteurs autorisés devront respecter les exigences réglementaires liées à des éléments comme les normes relatives au contrôle de la qualité et les mesures de sécurité. Cela réduirait les risques pour la santé et la sécurité de la population que constitue une telle production. Une fois le nouveau règlement entré en vigueur, les personnes intéressées pourront présenter une demande de licence et si elles sont admissibles, commencer immédiatement à produire et à distribuer de la marihuana séchée à des fins médicales.

Les parties qui envisagent devenir producteur autorisé et qui sont intéressées à prendre part à certaines activités de recherche et de développement, comme l'évaluation de la marihuana ou l'évaluation des conditions de culture sur place, peuvent le faire

under the Controlled Drugs and Substances Act (CDSA) and the Narcotic Control Regulations (NCR).

These mechanisms include

- a licence issued under section 9 of the NCR (licensed dealer) which would enable activities such as possession to test marihuana plant material;
- a licence to cultivate, gather or produce marihuana for scientific purposes issued in accordance with section 67 of the NCR; and/or
- an exemption issued under section 56 of the CDSA for other activities with marihuana such as testing packaging methods and materials.

Information and documents that would be considered in an application include but are not limited to

- a statement indicating that these research and development activities are being conducted with the intent of eventually applying to become a licensed producer;
- a declaration from the applicant that the municipality, local law enforcement, and local fire officials where the proposed activities are to be conducted have been notified of the proposed research and development activities with marihuana;
- valid criminal record checks of the person responsible for the licence or exemption, the person in charge of the research project, if applicable, and the person in charge of production, indicating that they have not been convicted, as an adult, within the preceding 10 years, of a designated drug offence or a designated criminal offence as these terms are defined in the NCR;
- a letter from the owner of the proposed location where the proposed activities are to be conducted indicating that there is no objection to its use for marihuana production if the location is not owned by the applicant; and
- appropriate security measures, in accordance with the requirements of the Directive on Physical Security Requirements for Controlled Substances found at www.hc-sc.gc.ca/hc-ps/pubs/precurs/dealers-distrib/phys_securit_directive/index-eng.php and the guidance document Building and Production Security Requirements for Marihuana for Medical Purposes found at www.hc-sc.gc.ca/dhp-mps/marihuana/future-avenir/securiteng.php.

In deciding whether to issue a licence or exemption, the Minister would review applications on a case-by-case basis and may consider other factors such as the risk to public health, safety or security. This would include the risk of marihuana being diverted to an illicit market or an illicit use.

It is also worth noting that if the proposed MMPR are promulgated, the issuance of a licence or exemption to conduct research and development activities does not guarantee the issuance of a licence under the proposed new Regulations. Producer licences can only be issued once the new Regulations come into force.

Interested parties wishing to conduct research and development activities may initiate this process by providing Health Canada with a letter expressing their interest and providing the avant l'entrée en vigueur du RAMFM en se servant des mécanismes déjà prévus par la Loi réglementant certaines drogues et autres substances (LRCDAS) et le Règlement sur les stupéfiants (RS).

Les mécanismes comprennent :

- une licence délivrée en vertu de l'article 9 du RS (distributeur autorisé) qui autoriserait des activités comme la possession pour évaluer les plants de marihuana;
- une licence pour cultiver, récolter ou produire de la marihuana à des fins scientifiques délivrée en conformité avec l'article 67 du RS;
- une exemption délivrée en vertu de l'article 56 de la LRCDAS pour d'autres activités liées à la marihuana, comme l'évaluation des méthodes et du matériel d'emballage.

Voici certains renseignements et documents qui seraient pris en compte dans une demande :

- un énoncé indiquant que ces activités de recherche et de développement sont menées dans le but éventuel de faire une demande pour devenir producteur autorisé;
- une déclaration du demandeur selon laquelle la municipalité, les représentants locaux de la loi et des services d'incendie où les activités proposées doivent avoir lieu ont été avisés des activités de recherche et de développement proposées avec la marihuana;
- les vérifications valides du casier judiciaire de la personne responsable de la licence ou de l'exemption, de la personne chargée du projet de recherche, s'il y a lieu, et de la personne chargée de la production, casier judiciaire où il est indiqué qu'elle n'a pas été condamnée, comme adulte, au cours des 10 dernières années, pour une infraction désignée en matière de drogue ou une infraction criminelle désignée, conformément à la définition de ces termes dans le RS;
- une lettre du propriétaire du lieu proposé où les activités proposées doivent avoir lieu et dans laquelle il est indiqué qu'il n'y a aucune objection quant à l'utilisation du lieu pour la production de marihuana si le lieu n'est pas la propriété du demandeur;
- les mesures de sécurité appropriées, en conformité avec les exigences de la Directive sur les exigences en matière de sécurité physique pour les substances désignées se trouvant à l'adresse suivante : www.hc-sc.gc.ca/hc-ps/pubs/precurs/dealers-distrib/phys_securit_directive/index-fra.php et du document d'orientation Exigences en matière de sécurité des bâtiments et de la production de marihuana à des fins médicales se trouvant à l'adresse suivante : www.hc-sc.gc.ca/dhp-mps/marihuana/future-avenir/securit-fra.php.

Dans le cadre de sa décision d'émettre une licence ou une exemption, le ministre examinera les demandes au cas par cas et pourrait tenir compte de facteurs comme le risque pour la santé ou la sécurité de la population, y compris le risque que la marihuana soit détournée vers un marché illicite ou que cette marihuana soit utilisée à des fins illicites.

De plus, veuillez prendre note que si le RAMFM est promulgué, l'émission d'une licence ou d'une exemption concernant le déroulement d'activités de recherche ou de développement ne garantit pas l'émission d'une licence en vertu du nouveau règlement proposé. Les licences de producteur ne peuvent être émises que lorsque la nouvelle réglementation sera en vigueur.

Les parties intéressées désireuses de mener des activités de recherche et de développement peuvent amorcer ce processus en faisant parvenir à Santé Canada une lettre dans laquelle elles information indicated in the first four points listed above, as applicable, at the following address:

Office of Controlled Substances Controlled Substances and Tobacco Directorate Healthy Environments and Consumer Safety Branch Health Canada, AL: 3503A Ottawa, Ontario K1A 1B9

Please note that if interested parties wish to conduct activities in addition to research and development, such as producing marihuana for the purposes of sale before the proposed MMPR are in force, those parties must comply with the applicable requirements of the *Food and Drugs Act* and the *Food and Drug Regulations* (e.g. requirements for clinical trials which demonstrate clinical efficacy and safety).

For those requiring more information regarding the application process or information regarding the availability of a legal supply of seeds or marihuana for research and development activities, please contact the Office of Controlled Substances at OCS-BSC@hc-sc.gc.ca.

manifestent leur intérêt et en communiquant l'information indiquée dans les quatre premiers points énumérés précédemment, s'il y a lieu, à l'adresse suivante :

Bureau des substances contrôlées
Direction des substances contrôlées et de la lutte au tabagisme
Direction générale de la santé environnementale et de la
sécurité des consommateurs
Santé Canada, Indice de l'adresse : 3503A
Ottawa (Ontario)
K1A 1B9

Veuillez prendre note que si les parties intéressées souhaitent mener des activités en plus de la recherche et du développement, comme la production de marihuana pour la vente avant l'entrée en vigueur du RAMFM, ces parties doivent se conformer aux exigences applicables de la Loi sur les aliments et drogues et du Règlement sur les aliments et drogues (par exemple aux exigences de mener des essais cliniques sur l'efficacité et l'innocuité).

Les personnes désireuses d'obtenir de plus amples renseignements sur le processus de demande ou de l'information sur la disponibilité d'un approvisionnement légal en graines ou en marihuana pour des activités de recherche et de développement peuvent envoyer un courriel au Bureau des substances contrôlées à l'adresse suivante : OCS-BSC@hc-sc.gc.ca.

[50-1-0]

[50-1-0]

DEPARTMENT OF INDUSTRY

OFFICE OF THE REGISTRAR GENERAL

Appointments

Name and position/Nom et poste

Dedimus potestatem

MINISTÈRE DE L'INDUSTRIE

BUREAU DU REGISTRAIRE GÉNÉRAL

Nominations

Order in Council/Décret 2012-1607

Commissioners to administer oaths/Commissaires à l'assermentation

Within Canada/à l'intérieur du Canada Bocock, The Hon./L'hon. Randall S. Gagné, The Hon./L'hon. Jocelyne Gleason, The Hon./L'hon. Mary J. L. Kane, The Hon./L'hon. Catherine M.

Within Alberta/à l'intérieur de l'Alberta Jones, The Hon./L'hon. Craig M. Millar, The Hon./L'hon. Bruce A.

Within British Columbia/à l'intérieur de la Colombie-Britannique Abrioux, The Hon./L'hon. Patrice Fitch, The Hon./L'hon. Gregory J. Jenkins, The Hon./L'hon. Robert W. Tindale, The Hon./L'hon. Ronald S. Weatherill, The Hon./L'hon. Gordon C.

Within Manitoba/à l'intérieur du Manitoba Rempel, The Hon./L'hon. Herbert

Within New Brunswick/à l'intérieur du Nouveau-Brunswick DeWare, The Hon./L'hon. Tracey K.

Within Newfoundland and Labrador/à l'intérieur de Terre-Neuve-et-Labrador McGrath, The Hon./L'hon. Rosalie

Within Northwest Territories/à l'intérieur des Territoires du Nord-Ouest Shaner, The Hon./L'hon. Karan M. Smallwood, The Hon./L'hon. Shannon


Within Nova Scotia/à l'intérieur de la Nouvelle-Écosse Wood, The Hon./L'hon. Michael J. This is **Exhibit "G"** referred to in the Affidavit of **TODD CAIN**Affirmed before me at the City of Ottawa, in the Province of Ontario, this 15th day of January 2015.


A Commissioner for Taking Affidavits

Sherri Laureen Szabados, a Commissioner, etc., Province of Ontario, for the Government of Canada, Department of Health. Expires December 2, 2015

Strains and prices offered by Aphria (22 total strains; \$8.30 - \$10.90)


Currently in stock:

























Not currently in stock:

















































Strains and prices offered by Bedrocan Canada Inc. (5 total strains; \$7.50)

Currently in stock:






plant type, beed because of its high yield, optimal growth chaise betsides, and derived from the popularly known tack florer."


connabis variety:


Back to Strain Varieties

THC 22% | GBD <1%









Bedrolite

THC>1%, CBD 9%

\$7.50

Representative Certificates of Analysis

Dougland Carlificate

Geographics variety is a "Saliva" dominant, surain of carbothic observer and the less than 18.1 (if and the CBO (content by regist). Bethollow is a valiable as a "granulated" or oduct.


About Bedrolite®

Bentrolitest possesses medium leyels of 'Cannatidio' (CBD) and ultration levels of THC content CBD's a medial ingradiest in cannatis that is non-psychiactive) it does not produce the typical sense of evaluate or discinentation that may typically he associated with consuming TRC.


Back to Strain Variaties


Strains and prices offered by Broken Coast Cannabis Ltd. (9 total strains; \$7.00 - \$9.00)


Currently in stock:





Not currently in stock:




















Strains and prices offered by Canna Farms Ltd. (62 total strains; \$1.75 - \$11.00)

| and interest the resistance of the second of | National American Commission Commencer Comments (Comments Comments Comments Comments Comments Comments Comment | alantin kindan hiddam kindan yang anakan kan kindan kindan kindan kindan kindan kindan kindan kindan kindan ki | patient a handley in the property and the property and the property of the pro |
|--|--|--|--|
| | | | |
| | LEMON SKUNK 57.50 pergrain 1967HC J Dev CSD | CHEMS 22.00pergran 154.1HE TOTALSBO | SUPERBUD S. D. Ser (1981) 18 THE J. ONN CRD |
| PLUSH SERRY \$7.50 Ser gran 15% INC 43% CSD | GREEN CRACK 3.000 per gram 35.00 per gram | REDICHERRE BERRY 35.00 per grant 28.20 (1.00s.co) | CASCALLAND AND THE STREET OF T |
| | NYC DIESEL 50.50 per gram 7% THE 04% CR0 | SHAKE STO per perc STOR per perc SWITHE EASK COD | 100% SATIVA SHAKE SASO PET BRID ASSASICE (IDSECTED) |
| | SOUR DIESEL SOUR DIESEL SOURCE AND CONTROL DIESEL DE SOURCE AND DIESEL DE | MASTER KISH SOULDER JOHN 25% THE J. 128 COD | GIRLS COUT COOKIES 21070 per gram 25% THC 16.2% CBB |
| PINK KUSH Skott per gran one the house CED | CBD SKINNK HAZE VINITER 2014 Hybrid: High CBD | CANNATONIC WINTER 2014 Hybrid - High CRD | |

Full list ("Version 1") as presented on website:

ANIMAL COOKIES (BC Bud)

ATOMIC SHIVA (Dr. Atomic)

BANGHI HAZE (ACE)

BC ROCKSTAR (NA)

BLUE CHEESE (Jordan of the Islands)

BLUE DREAM (Humbolt)

BLUE WIDOW (Jordan of the Islands)

BLUEBERRY (Jordan of the Islands)

BLUEBERRY JAM (Dr. Atomic)

BUBBA KUSH (Humbolt)

BURMESE KUSH (TH Seeds)

CANNATONIC (Resin Seeds)

CBD KUSH (Dutch Passion)

CBD SKUNKHAZE (Dutch Passion)

CHEESE QUAKE (TGA Subcool)

CHEMDAWG (Humbolt)

CHEMO (Jordan of the Islands)

CHERNOBYL (TGA Subcool)

CRIMEA BLUE (Barney's Farm)

CRITICAL MASS (CBD Crew)

CRITICAL SUPER SILVER HAZE (Delicious)

DRAKENSBURG GOLD (Malawi Seeds)

DURBAN POISON (Dutch Passion)

FLO (DJ Short)

GIRL SCOUT COOKIES (BC Bud)

GOD'S LEMON SKUNK (Jordan of the Islands)

GREEN CRACK (NA)

HEADBAND (Loud)

JACK HERER (Sensi Seeds)

KALI MIST (Serious)

KOOTENAY STAR (NA)

KOSHER KUSH (DNA Genetics)

LA CONFIDENTIAL (DNA Genetics)

LEMON SKUNK (Jordan of the Islands)

MANGO (BC Bud)

MASTER KUSH (NA)

MK ULTRA (TH Seeds)

MOTIVATION (BC Bud)

NORTHERN LIGHTS x HAZE (Paradise)

NYC DIESEL (NA)

PINK KUSH (NA)

PURE KUSH (Greenhouse Seeds Co.)

PURPS (Jordan of the Islands)

RECON (DNA Genetics)

RED CHERRY BERRY (Barney's Farm)

ROCKSTAR (BC Bud)

SEAWARP x POLECAT (Reeferman)

SENSI STAR (Paradise)

SHAMAN (Dutch Passion)

SHIATSU KUSH (BC Bud)

SKUNK #1 (Sensi)

SLEESTACK (DNA Genetics)

SOUR DIESEL (Reserva Privada)

SPACE JILL (TGA Subcool)

STRAWBERRY COUGH (Dutch Passion)

SUPERBUD (Green House Seeds Co.)

SWEET TOOTH (BC Bud)

TANGERINE DREAM (Barney's Farm)


THE OG #18 (Reserva Privada)

THE ULTIMATE (Outch Passion)


WHITE RHINO (Green House)


WHITE WIDOW (Seedsman)

Strains and prices offered by CanniMed Ltd. (7 total strains; \$7.00 - \$13.50)















Strains and prices offered by Delta 9 Bio-Tech Inc. (Note: Unable to obtain this information from Delta 9 Bio-Tech's website. The below screenshots are taken from the http://www.can.md/ website. [28 total strains; \$6.00 - \$9.00])

Strains Sold by Delta 9



Indica


Citrus Haze Double Dutch King's Kush by Delta 9 by Delta 9 by Delta 9 (2 reviews) (1 review) (western) THC THC THC CBD | CBD | CBD \$6 \$7 \$8 Sativa Indica Indica Mofavation OG Kush Serious 6 by Delta 9 by Delta 9 by Deita 9 (1 review) (1 review) (1 redow) THC BARRETS THC THC CBD I CBD | CBD \$7 58 unknown orice Indica Indica Sativa Chronic Kali Mist White Russian by Delta 9 by Della 9 by Delta 9 (Treview) (Treview) (Teview) THC THC THE RES THC CBD | CBD | CBD | \$7 **\$9** \$9 Hybrid Sativa Sativa Bubble Gum CBD Skink Haze Cannatonic by Delta 9 by Delta 9 by Delta 9 (no reviews yet) (no reviews vel) (no reviews yet) THC unlatered THC MAN THC FAR CBD CBD CBD Unicount unknown LETIKO 1911 unknosa dice price Disco

Hybrid

Hybrid

ChemDog

by Deita 9



(no reviews yet)

THC UNIT OWN

CBD usaknown

unknown pianttype unidown orice

\$8

El Mino

by Delta 9



(no reviews yel)

THC ...

CBD |



Indica

Great White Shark by Delta 9

\$7

\$7

(no reviews yet)

THC

CBD |



Indica

Pure Kush

by Delta 9



(no reviews yet)

THC

CBD



Indica

Skunk Haze

by Delta 9



(no reviews yel)

THC BESS

CBD




Hybrid

unknown orice

\$7

Warlock

by Delta 9



(no reviewa yel)

THC

CBD |



Indica

White Phino

by Delta 9



(no reviews yei)

THC USSCHOWN

CBD (KINGSON)



Indica

unknown

price

Strains and prices offered by In The Zone Produce Ltd. (Note: In The Zone's website does not include this information. The below screenshot is taken from the http://www.can.md/ website. [5 total strains; price range unknown])

Strains Sold by In The Zone

17

by In The Zone



(no reviews yel)

THC unicerown

GBD unimown

cakaova plani iyae unknown price Green Ogopogo

(GO)

by in The Zone



(no reviews yel)

THC Unknown

CBD unknown

инізпоки ріані іуре unknossi price Hindu Kush

by in The Zone

(no reviews yell)

THG unimous


CBD unknown

unionem plantique

tankarovan paloe

Purpie Candy

by in The Zone



(no reviews yet)

THC uniques

CBD Usinown

unianown piani byce univioen Pice White Kush

by in The Zone



(no reviews yat)


THC USKNOWN

CBD UTINGOWA

unknosm planttype

inknown price

Strains and prices offered by Mettrum Ltd. (15 total strains; \$3.60 - \$9.60)



Strains and prices offered by MariCann Inc. (8 total strains; \$7.00)

Currently in stock:











Not currently in stock:





iCann Balanced Low



Strains and prices offered by MedReleaf Corp. (16 total strains; \$2.50 - \$15.00)

Currently in stock:







Solveris

A premium blend of our trimmings.

THC Range: S-TON CSD Range: 0%

INDICA: N/AS SATIVA: N/AS

C C https://medreleaf.com/shop/cognibre-2



haddaay ayndy

ANOUT PATIENTS

vis *Physica*

UCIANS

INDIVATION

Siack

FACE

ČVINTĖKOM ING

Cognitiva



A UK favorite renowned for its distinct cheese fragrance.

THC Range: 12-14%

CBO Range: 0%

INDICA: 40%

SATIVA: 60%



| Reported To Help | wind store is | | |
|----------------------|------------------|-------------------|-----------|
| disorder (PTSD), spa | | | |
| Palace & Aroma | re comme | | |
| - Gerretics | | | ir da est |
| | \$12.50 | acanada Marasa | |
| ather-basilished | Alexandia (Base) | aire in Carl | |

| C E http://medrelad.com/shoy/pxtants | | , and |
|--|---|-------|
| Engja (Register | A contract of the contract of | |
| MEDRELEAE ABOUT DATEMES PRESIDENCE INMOVATION SHOP FAG O | CONTACT US | STANT |
| | error (40 57865 oc. vibrarium e apecigiono, e | -90- |





Potentia

A world-renowned, best-selling Kush variety.

THC Range: 9-12%

CBD Range; 0%

INDIÇA: 75%

SATIVA: 25%

| | | | | | | | | | | | | | | | | | Ŧ. | | |
|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|----|--|--|
| | | | | | | | | | | | | | | | | | | | |
| | | | | | | | | | | | | | | | | | | | |
| | | | | | | | | | | | | | | | | | | | |
| | | | | | | | | | | | | | | | | | 2. | | |
| | | | | | | | | | | | | | | | | | | | |
| | | | | | | | | | | | | | | | | | | | |
| | | | | | | | | | | | | | | | | | | | |
| | | | | | | | | | | | | | | | | | | | |
| | | | | | | | | | | | | | | | | | | | |
| | | | | | | | | | | | | | | | | | | | |
| | | | | | | | | | | | | | | | | | | | |

appeale, attention delicit disorder (ADD), articleis, lack of appeale. caucer treatment symptoms, inflammation, insemmia, joint poin, moderate pain, symptoms.

| Pal | | ×. | 74 | | | | 200 | 77. | 100 | 3 . | | · | | 1. 1. | | ∹^. | Limit. | | | | | | 4 | | 200 | |
|------|----------------|-------|----------|------|-------|-----|------|-----|------|-------|-------|-----|-------|-------|-------|-------|--------|--------|-------|-------------|--------|------|--------|---|---------|--|
| 7 X4 | w. | - | 34 | 134 | 11.4 | 7 | 7. " | | | | *** | | 1 | 40.0 | | | * . | | 200 | | | | 4000 | | 10 | |
| 4 | | : : | ٠. | • | 2.5 | | 11.0 | | 100 | | | -3. | 1.5 | 4.0 | 1114 | | 100 | · ii : | : ''! | | | | 141.14 | ::::::::::::::::::::::::::::::::::::::: | 7.44 | |
| | and the second | 244 | Acres in | نمثذ | وفيلة | 300 | 100 | 100 | | N. 1 | -2. | | | | | | | | | | | | 970.00 | 11.71 | 1 21 | |
| | | | | ALT. | **** | - | | | | | | | | A | . 25 | | 200 | Z | 37.2 | -::: | 200.00 | 200 | | 380 P. | 27.XX | |
| 1000 | | | - 445 | | | - ; | | 140 | 3.3 | | | | | | 1.4 | 5 | - 33 | | | v. 13 c | 100 | 1000 | 10.7 | | 4.00 | |
| Ger | | | | | 100 | 1.0 | | 000 | | 2 7 . | 100 | | de le | | 1 . 2 | | · 613 | 122 | 5.7 | | | | 1 27 | | 1. 11 | |
| A.C. | SCE | | 1177 | 2. | | | 200 | | 99. | | evv | | | | 100 | - 200 | E :- 1 | :: | | | 200 | 200 | M DE | | | |
| | 7 | | • " | 55. | 1,00 | | - 15 | ٠., | 1.0 | | | | | | | 1.5 | | | | | . 777 | | | | 1.1 | |
| ide | March. | تبذيه | and a | | | | | | - 20 | . 2 | - 7.7 | 100 | | | | | | | | | 10.00 | v | |) in a | c 1,000 | |
| | | | | | | | | | | | | | | | | | | | | | | | | | | |

| C & intra://medgeleaf.com/stop/banasufflum |
|--|
| |
| Login i Projeties 😹 (on sin |
| |







Tranquillum

A combo of two of the world's premium varieties,

THC Range: 10-13%

DEDICA:: 73%

SATIVA: 25%

Reported To Help With: anxiety, attention deficit disorder (ACD), concer treatment symptoms, depression, headaches, lack of appente, noclerate pain, nausea

\$10.00

| ← C 自https://medreleaf.com/shop/ycluptig | Salvatera de la composito de l La composito de la composito d | | | | | | | |
|--|--|----------|------------|------------|------|-----|------------|--|
| WEDRELFAE 198 MEDICAL STATURE | ŸSCHLL | PATERĄZS | PAYSICIANS | BINOVATION | SHOP | FAQ | CONTACT US | |





Voluptas

Cenesics

A sativa variety known for its sweet flavor. THC Range: 16-21%. CBD Range; 0%. INCHCA: SOX SATIVA: 70% Reported To Help With: cancer treatment symptoms, depression, chronic fatigue, filtromyalgia, headaches, moderate pain, post-traumado siress distorder (#540). Palete & Aroma

\$12,50

C Si https://medreleaf.com/shop/cerebri Login (Register 🐒 🖂 🖂

.ละกระการใกษณ



Cerebri

A high THC indica known for its potency.

THC-Range: 19-22%

CSO Kange; os

INDICA: 80%

SATIVA: 20%

Reported To Help With.

artivitis, cancer treatment symptoms, Colles, Crotic's disease, digestive problems, inflammation, inflammation howel disease (1812), irritable howel syndromic (1851), in sound o, lack of appents, severe pain, spasticle,

Palate & Aroma

ACCORDING 1





Sedamen

| A particularly strong sedat | ive Kush variety. |
|---------------------------------|--|
| THC Range: 19-25% | CBD Range: 0% |
| INDICA: 85% | SATOVA: 15% |
| Reported to Help With | |
| headaches, inflammation, inflam | ni symptoms, Colois, Crobn's disease, manay bowei disease (180), irritable Buk of appente, severe pain, John boin. |
| Palate & Arona | |

Login | Register | a lands





| Jane. | ٠ | | | | ٥, | | |
|-------|---|-----|---|----|----|----|-------|
| C | 1 | -26 | 2 | Ř | 7 | * | v 🐠 . |
| | æ | 3.3 | Æ | 4. | 4 | 47 | L.S |

| THE Range: 13-15% | CSD Range 0% |
|--|---|
| INDICA: 40% | KOD KVITAZ |
| | |
| Reported To Help With | |
| cancer freatment symptoms, die pain, lack of appetite, post-mau | enslic suers disorder (PISO) Periodens, eye pressure, mode |
| Palate & Aroma | |
| Genetics | |

SALESS ESTINA



MEDITELEAE

ASOUT

PATTENTS-

PHÝSICIANS

INNOVATION

SHOP

MQ CONT

CONTRACTANC

∖ Limiled Ci∋Edillion





MONTH PRODUCTION -

Articulus

An exotic hybrid with remarkable white flowers.

THC Range: 11-16%

CSD Range: 0%

INDICA; 60%

SATIVA: 10%

Reported To help With

Inflammation, joint pain, moderate pain, anxiety, post-trainmatic stress disorder (FISD), heafaches.

Fainte & Aroma

+

Conetics

\$1250 (1997) Herender

Not currently in stock:







Alaska

The highest recorded THC sativa variety.

THC Range: 19–21%. CBD Range: 0%
INDICA: 50% SATIVA: 70%

| Reported To Help With: | | | |
|--|----------|-------|----------|
| The state of the s | ucarium. | SALL. | 1,100,00 |
| chronic pain, neusca, loss of appenie, 182, croint's disea | sz, co | | |
| Palate & Arone | | | 147 |
| Centerics | | | |
| and the second s | | | |

\$15.00 \$15.00/g \$15.0

SE SPECIAL DESIGNATION

+ C I fictos (/medreleaf.com/shop/dutabilis

Logui J Register. 4/2 // // C



about fatights physicians bundyation shop faq





Durabilis

An all-time classic.

THC Range: 14-17%

CHIL Range: (N

INDICA; 60%

SATIVA: 40%

| anxiety, headach | cancer e, lack | treatn of app | etite, | vinp mild | toms pair | , de | 27E5 | ston | , eye | į. | SSE | e, | e de la constante de la consta | |
|---------------------|-------------------|------------------|----------------------|--------------|--------------|------|------|------|-------|------|-----|----|--|----|
| Palaie s | k Avon | 18 | (1 | | 170 | | | | T. | | | | | 1 |
| Cenets | 3 H | | | | | 100 | | des. | | , sp | Ø | | | Ţ, |
| | | | 1900 1900 1900 | | \$7 | .50 | | | | 16 | | | | |

4 G få https://medreleaf.com/shop/midnight MEDRELEAR. PATIENTS SHYSICIANS INNOVATION SHOP Midnight. A unique variety with a nearly 1:1 ratio of CBD/THC. CBD Range: 9-11% THE Range & LOW INENCA: 40% SATTVA: 60% Reparted To Help With atzhelmer's disease, anxiety, arthitis, Concer treatment symptoms, chronic fatigue, Collies, Crohin's disease, fibromyzigia, bendaches inflammenton, irmalife Boivel syndrome (185), lack of appente, mild pain, mausea, Maltiple Sciencial (MS), post-treumatic stress disorder (PTSD); \$12.50 \$12.50/0 Coming Spent estroctorio (1,00) ← ≥ C @ https://medreleaf.com/shop/avidekel Logia Register 💰 👙 AviDekel The world-renowned, high CBD, low THC variety. THC Range: 0.7-1.0% CBD Range: 13-17% INDICA: 50% SATIVA: 40% Reported To Help Walt alzheimer's disease, ambritis, cancer treatment symptoms; Crobn's disease, circuit fatigue, Colins, Algestive protisens, epilepsy, filtromysigla iditaromation, inflammatory bowel disease (160% irritable bowel syndroma (163), nausea, mild pain, Miltiple Scierosis (145), Parkinson's disease, seizures.

\$12.50 \$\frac{1}{2}\$\$
\$312.50 \$\frac{1}{2}\$\$
\$312.50 \$\frac{1}{2}\$\$
\$\frac{1}{2}\$

Palate & Aroma

← → C S https://medreleaf.com/shop/erez

MEDRELEAR.

patients physicians uniquation shop fac compactus





Liez

Israel's best-selling high THC variety.

THC Range: 18-20%

COO Range; Ox-

INDICA: 70%

SATIVA: 30%

Reported To Help With

amyotrophic laberal sclerosis (ALS) or Low Geliniy's Disease, carrier treatment symptoms, Collets, Crober's disease, disesting problems, inflammators bowel disease (BDS), insommia, firmable bowed syndrome (BDS), maybe spayms, post-treatments strays district (FESD), severe path, spasms, Tourene's syndrome.

| skupy Supering productive or | | + |
|------------------------------|----------------------|---|
| 2.4.5 | 1515.00 | |
| | German de la company | |

\$97.6 Chip., p., 227.4

・ C 含 https://medreleaf.com/shop/relevo-v

Logio i Register 🥡

PATIENTS PHYSICIANS INNOVATION SINCE FAQ CONTACTUS



Relevo

A popular kush variety.

THC Range: 13-16%

CED Range: OK

INDICA: 40%

SATIVA: 60%

Reported To Help With attention deficit disorder (ADD), auxility, cancer treatment symptoms, headaches, feck of appetits, mild pain, nausea. \$10.00 \$10.00/g

Coming Scort

WANTED THE





ABOUT

TENTS PHYSIC

HYSECULNS:

INNOVATION

SHOP

LAG CONT

CONTACT US





Sonnium

A rare variety suitable for mild relief.

THE Range: 16-21%

CSU Range: 0%

INDICA: 80%

SATIVA: 20%

Reported To Help West:

mild pain, Lack of appende, ADD, Cancer meanment symptoms, Nausea,
estsD, Anxiety:

Palate & Aforna

Correctes

| dan marana 🥍 | 2,50 |
|--------------|-------|
| Comm | 150/g |


- T. C. SARRIET -

Strains and prices offered by OrganiGram Inc. (15 total strains; \$6.00 - \$9.00)

| · | ORGANIGRAM ADOLT | Products Doctors Patie | ents Investors Blog Français |
|--|-------------------------------------|---|--|
| | STIMULATE APPETITE, CONTROL NAUSEA | When patients are dealing with a condition or treatment where a side effect or symptom is a lack of appells or nausea. Organifican ACN strains can help, aspecially for ffly patients or those undergoing | STRAN CHETICS CONTACT SCHOOLS INTER LANGUAGE LAN |
| | ANXIETY AND STRESS DISORDERS | Anolety and Stress Blaceders are complicated topics that do not always respond to traditional testments. If you are suffering from such disorders, speak to your doctor about how OrganiGram ASD strains | STOCK CONTICS SECOND STOCK STOCK SECOND SECO |
| | DIGNITY, COMPORT, QUALITY OF | When caring for a loved one with a terminal illness. Organifician DCQ strains are specially engineered and produced to provide patients with the highest level of relief we can provide. | CRAN DEPO SEQUENCE OF CONTROL OF |
| Thanks for your interest! Can we help you with anything? | MANAGING CHRONIC PAIN | Organiciran's MCP selection of strains provide an analgesic (pain killing) effect, particularly when ealers, that can improve the comfort level of patients sofiering from Chronic Pain significantly. | STANE CONTYS SCENE Hard City - Post to but to be Silved Control of the Control |
| Partie Mon Estail & Courted OHAT & CHATTEZ | NEUROLOGICAL DISORDERS & SPASTICITY | Organiscian NDS strains are designed for patients suffering from neasological disorders and spasticity, enabling them to receive the necessary antispasmodic effects without compromising their libertyle. | STRUM CENTELS SEGRAM- Johan Voice-Associate 17 Johan Voice-Associate 17 John Voice-Associate 17 John Voice-Associate 17 John Voice-Associate 17 John City Man Coupts |

Strains and prices offered by The Peace Naturals Project Inc. (19 total strains; \$3.00 - \$6.00)


Currently in stock:





CBD level: < 0,95% THC level: 6%

Not currently in stock:





Chrome

The Chrome variety is a cousin of one of the most popular varieties in California. This Cannabis has been reported to have a very strong and immediate head pain relieving effect. Chrome has been reported to be long facting with a lathargic period that is followed by appetite stimulation and sleepiness.

CBD level: < 0.1% THC level: 20%






Nyce N' EZ - A Milled Variety by Request

At the request of some of our valued clients we are pleased to offer our first three N° EZ to use, course ground meditinal Cannabis. Our first, pre-milled offering is a quick and easy solution for your medicinal Cannabis consumption. Nive N° EZ is a "bland" of some of our best medical varieties. Nive N° EZ is a mild blend, with a mid-range THC level that clients have noted to provide an energetic and uplifting feeling, generally best for day time use. This blend has been suggested for use in pain management and helping to settle nauses. Nive N° EZ appears light and rick green with kints of purple.

CBD fevel: < 0.05% THC level: 10.8% Price per gram: \$4.50 (Sold Out)







Nyce N' Evening - A Milled Variety by Request

With the increasing demand for our ground product Nyce N° E2 we are pleased to offer our first Nyce N° Evening to our exclusive Peace Naturals Clientels. This course ground medicinal Cannabis is now our 2nd pre-milled offering is a quick and easy solution for your medicinal Cannabis consumption. Nyce N° Evening is a 'biend' of some of our best medical varieties that provide the medicinal effects that many of our clients have requested for exening use. Nyce N° Evening is a rich blend, with a mid-range THC level that clients have noted to provide a elegible and tired feeling, generally best for night time use. This blend has been suggested for use in pain management, hunger management and helping to settle nausea. Nyce N° Evening appears light and rich green with timts of orange and pumple.

COD level: < 0.05% THC level: 15.7% Price per gram: \$4.50 (Sold Out)





Spirit

Spirit is a new variety of medicinal Cannabis created by Peace Naturals in an effort to have medicine that works to effectively lift your spirits. This higher THC variety that is an Indice/Sativa blend has been reported to have a gentle, mood enhancing, pain referring effect. Please enjoy in moderation as this is statistically one of our greater strength varieties.

CBD level: <0.05% THC level: 21%

Price per gram: \$6.00 (Sold Out)



C B https://peacenaturals.com/products/



Nyce N' CBD - A Milled Variety by Request

Nyce N° CBD is another 'blend' of our best medical varieties that provide the medicinal effects that many of our clients have requested for pain relief with mild euphoric affect, Nyce N' CED is a smooth blend with a mid-range THE level that clients have suggested for use in pain management, hunger management and helping to settle nausea.

CBD level; < 6.1% THC level; 8.4%

Price per gram: \$5.00 (Sold Out)



Daisy is a mild variety that provides wonderful 'during-the-day' medication with 6% 1940 and <8.05 CBD. Available for a limited time only.

CSD level: < 0.05% THC level: 6%

Price per gram: \$3.00



두 글 C 집 https://peacenaturals.com/procints/






Rio

higher THC varieties therefore it can be called one of our most potent. The effects of Rio are long issting, heavy but not alsepy. Some have experienced pain relieving benefits described to be most effective in the limbs, upper neck and lower facial regions. Rio's dried flowers are generally small and dense.

CBD level: < 0.4% THC level: 18%

Price per gram: \$6.00 (Sold Out)



Nina has been reported to provide substantial pain relief with little to no noticeable euphona. Clienta describe Nime as pleasant and uplifting with little to no lethargic response. Our Nina variety is beat suited for those clients who may require Cannabis throughout the day.

CBD level: 7.6% THC level: 9.7%

Price per gram: \$5.90 (Sold Out)



← C 8 https://peacenaturals.com/products/





Jenni

it is a mid-level THC count. Jenni provides a light sensation that has been described as both stimulating and musde/joint pain relieving. As a Sativa, the died Jenni flowers are often langer in shape and not as tightly compact as some other varieties.

CBD level: < 0.2% THC level: 10% Price per gram: \$6.00 (5eld Out)





Happy Feet

Happy Feet has been described as a light and energetic neuropathic pain relieving Connabis. This uniquely uplifting variety is a client favourite for daytime use. Client feedback describes Happy Feet to provide a pleasant body sensation, increase in motivation and an increase in productivity.

CBD favel: < 0.1% THC level: 18% Price per gram: \$6.00 (Sold Out)



+ C & https://peacenaturals.com/products/





Cupid

Cupid has been described by clients to provide a complex mixture of pain relief without the extended effects of lethargy. Clients chose Cupid for its smooth flavour and finish. Unique to any variety we have, Cupid is a skorter term pain relieving Cennabis.

CBD level: < 0.5% THC level: 15%

Price per gram; \$6,90 (Sold Out)





M.D.

M.D.'s high THC content makes it one of the strongest Sativas. This strain is known for its power and for its cerebral stimulation, a mostly Sativa plant that delivers great medical relief. This strain is favoured for its short flowering period, mold resistance and high yield. The lime green flowers deliver an earthy and amouth consumption making it a choice strain for new patients,

C80 level: < 0.95% THC level: 13.2%

Price per gram: \$6.00 (Sold Out)



는 글 C 집 https://peacenaturals.com/products/





Barry White

As it's name suggests, our Barry White variety is very smooth and relaxing. Barry White's hybridized genetics offer complex medical effects including a typical exphoric feeling as experience with most Sativa dominant varieties at low doses and significant body relaxation at larger doses. Current feedback suggest that Barry White provides an uplifting feeling that is perfect for daytime use and good for relieving arxiety and muscle

CBD level: < 0.4% THC level: 17%


Price per gram: \$6.00 (50% Out)



Avi is our two-to-one CBD to THC variety that is a 50 / 50 Indica and Sativa hybrid. It has a very distinctive, pungent smell that does not carry though the smooth oral sensation when smoked or eaten. Ckents have commented on the fast acting pain relief properties associated with Avi, as well as relaxing and calming effects.

CBD level: 9.5% THC level: 5.5%

Price per gram: \$6.90 (Sold Out)







Marcela

This equally Setiva and Indica variety has been reported to be a more social and enjoyable attempon / evening variety of Cannabia. Client feedback indicates Margela can provide pain relieving effects throughout the body, Marcela is a mid THC and lower CBD combination.

CBD level: < 0.05% THC level: ±0.5% Price per gram: \$6.90 (Seld Out)

HOSTERT



Happy Face

Happy Face has been described recently by clients as a delightfully uplifting head and upper body pain reliever. Descriptions have also included adjustives like Euphoric and Joyful, Our Happy Face variety has been used by clients in social settings and daytima use.

CBO level: < 0.3% THC level: 16%

Price per gram: \$6.00 (Selá Out)



C & https://peacenaturals.com/products/



Raphael is a very potent and strong THC variety of medicinal Cannabis. Reported tilent effects are powerful headache relief and strong appetite encouragement. Raphael is named after the godfather of Cannabis, Prof. Raphael Mechoplam, and as a potent variety it is therefore not for the inexperienced medicinal Cannabis

CBD level: < 0.85% THC level: 29.2%



The Grail

The Graft is known to peak the interests of the user's mood. From motivational to conservatively extensic, the Grail has the potential to provide a wide range of medicinal benefits from pain relief to appetite stimulation. This high THC Cosmobis variety is the bost in class. The Grail variety, predominantly Indica, grows bulky rather than tall and the dried flower is a rich dark green colour, remaining small and fairly dense.

CBO level: < 0.3% THC level: 17%

Price per gram: \$6,60 (Sold Out)

Strains offered by Tilray (Note: Tilray's website only provides a "sampling" of their strains and does not list the individual prices

| を含める A bitos://www.tilray.ca/en/Hom | | | | | <u> </u> | -Cinchastinii. | |
|-------------------------------------|--|--|--|--|--|--|---------------------|
| | ∠ TILRAY | WOR MOL | HOW IT WORKS | SHOP | RESIDUACE CENTRE | AROUT | FAI1 |
| | Type, Indius | | i (o) maio e na iliana de alcande e na iliana | Name of the Control | | ENERGY OF THE RESIDE | MORROW MINISTER |
| | Barbara Sud alsa a sam aeso s n osa | и при при при при при при при при при пр | MANGARINA Medican remaining specifical | · · · · · · · · · · · · · · · · · · · | and the commence of the control of t | комистон одовен о довеј | MANUFACTURE |
| | Subba Kush sakan sa nora na sa sap | | | | | Visit of the second | WOODINAVO. |
| | Diamond OG | Mohilikaaysikkassoo ka saata saasaa saasaa saasaa saasaa saasaa | NOMS (Alland Voltage of Transport Contractions | CANTONIO CHOMINA | 129400 Y 200202 C C C C C C C C C C C C C C C C | AND THE RESIDENCE OF THE SECOND | EMASSISA correct |
| | Puple Kush %2 std 64 to 64 to 64 to 6 | vergonaanssenamanssenamanskerkalen koksilinkerk herkilisterkerk | 6596 (GPONONIA) (CONTINUENT AND | diambiranaumsia | | 00000000000000000000000000000000000000 | HOOD THE SECOND |
| | Rockster GF (GB) Ab + OF GB C & B BU AB THE | NGT SECTION SEC | DANGER SENERAL SERVENCE | THE STATE OF THE S | Bross and 7 responsible to the control of the contr | POSTOCKUS SOCIOLOS | NoNellaherbacete |
| | Type Hybrid | | uy foliafensakii misendensi kwan indensif Nebesahii k | NOTE OF A SECURIO | No. | National of Pales Viscours | |
| | Equinox we say a 1982 this have day of | PNP-Prince-Prescription and account of the contract of the con | > 42 Self in 40 Self in 200 Se | Noteberes accencioness | entre de la companya | accession of the contract of | Prolessossissis |
| | OG Kush 6362300 eese at 3 see 119 interior terrotooneerick metataan oo | | | - manuscraft Ladinal DV (| eridan rosssanas socialas sakssocialas kas significações saks social | Ankalariaeokusunaa-ruossa | annocumpaga, jung |
| | OG Shark * 4 * 4 * 4 * 4 * 4 * 4 * 4 * 4 * 4 * | O Allaini Markini Markini Andrewski (Andrewski Markini Markini Markini Markini Markini Markini Markini Markini O Allaini Markini Marki | ance commencia a conferencia del 2012 de la compansión de la compansión de la compansión de la compansión de l | Sittli i wakala w | | ngmooreonementelijijo | Med-Hillington Naza |
| | Pink Kush e e se ene e e e e e e e e e e e managementation de energia de ener | CVA-Figure Park Seal Seal Seal Seal Seal Seal Seal Seal | | Arkstensononum serbe | ognoment varieties og til state o | el sonierco ressenta scompy | 9949646804902X |
| · | Tyse: Ngc ces | - CONTROL AS TO MAKE A TO MAKE A | ANNO CARAGON POLICION NO PORTO CARACTERISTA | NAME OF THE OWNER O | kritimener megemenen ger (z. c.m.; teks kolationske) | napitalist namatasiste sensit | (DANG) Paleonerus |
| | Afghani CBD (Indica) S S S S S S S S S S S S S S S S S S S | TO COLUMN TO A PROPERTY OF THE STREET OF THE | newsonancescommunication (Addition) | ocograpio monecono | dilikinin humanoo too manoo too amaroo dhaqadayo | Harman Marian In Joseph | KENDARONSONO ' |

Strains and prices offered by Tweed Inc. (25 total strains; \$5.00 - \$12.00)

Currently in stock:

Available





(Nordle)



BUDDY

(L.A. Confidential)



FOX HUNT

(G13)

\$6

\$5

\$7



HERRINGBONE

(AK-47)

\$9

Not currently in stock:

| Coming Soon |
|-------------|
| - |

| Coming Soon | | |
|-----------------------------|--------------------------|------------------------|
| | | |
| (x6) | (9) | (28) (0) |
| BAKERSTREET (Hindu Kush) | BALMORAL (UK Cheese) | BIRDS EYE (Jack Herer) |
| \$6 | \$3 | \$9 |
| (36) | | (22) |
| BOGART (OG Kush) | CHEVIOT (Black Widow) | CLARENCE (Chocolope) |
| \$\$ | \$ \$ | \$9 |
| (# <u>5</u>) | (22) G | |
| CLEARWATER | DOMEGAL | HIGH LANDS |

| | $\left(\begin{array}{c} 22\\ \hline 0\end{array}\right)$ | (<u>ar</u>) |
|------------------------|--|------------------------------------|
| CLEARWATER (Kali Mist) | DONEGAL (Chem Dowg) | HIGH LANDS (East Coast Sow Diesel) |
| ė i n | **** | B to A |



HOUNDSTOOTH

(Super Lemon Haze)

\$9



LECNIDAS

(Super Silver Haze)

\$6



(Cocoa Kush)

99



ROTFORK

(Bubba Kush)

\$12



NOVA

(Permywise)

\$9



FRACETON

(Ghost Train Haze)

\$12



SIATY THEFE

(Checolate Chunk)

\$9



TWILING

(Deep Purple)

\$9



WALES

(Space Bomb)

\$5



(Kosher Rush)

WESTACOO

(Plushberry)

YORKSHIRE

(Headband)

\$11

39

29

Strains and prices offered by Whistler Medical Marijuana Co. (18 total strains; \$12.00)

| currency in Stock: |
|--|
| CBD SHARK |
| \$12 Igram Inc. shipping |
| ORGANICALLY GROWN |
| THC 5.7% = 6.8% (actival level as rested) |
| CBO 4.8% - 5.7% (actual level as tested) |
| TYPE Indice Deminant Hybrid |
| GENETICS: Shark Shock x (unknown high CBD variety) |
| OTHER NAMES: eVa |
| AVAILABLE NOW |

Not currently in stock:

| GIRL SCOUT COOKIES | LSD | WHITE WIDOW |
|-----------------------------------|-----------------------------|---|
| fyram inc. shipping | /green inc. shipping | Igram inc. shipping |
| ORGANICALLY GROWN | . ORGANICALLY GROWN | ORGANICALLY GROWN |
| THC (ownting testing) | THC (awaiting sessing) | THC 21% - 23% (actual face) as server) |
| CBD lowaiting resting) | CBD (ossoiting testing) | CSD < 0.006% (natual level as rested) |
| TYPE Saxvis Dominace Hybrid | TYPE lodica Dominant Hybrid | TYPE: Indica Commant Hybrid |
| GENETICS: OG Kush x Durban Poison | GENETICS: Skunk #1 x Mazer | GENETICS: the genetics of this strain are unknown |
| OTHER NAMES of a | OTHER NAMES (1/4 | OTHER NAMES: White Shark, Peace-Maker |
| AVALLABLE MID DECEMBER | AVAILABLE MID DECTAIRER | ADALLABLE MID DECEMBER |

| BLUE BLOOD | ANIMAL COOKIES | FIRE OG | CANNATONIC | Blueserry Lambsbread |
|-------------------------------|---|--|--------------------------------|--|
| lgram isc. shipping | Agrave inc. skipping | fgram inc. хігірріну | Lyram isa, shipping | egram ins. skipping |
| ORGANICALLY GROWN | ORGANICALLY GROWN | OBGANICALLY GROWN | Organically Grown | ORGANICALLY GROWN |
| THC (aveating testing) | THC (awaiting testing) | THC fowarting testing! | THC loyalting testing) | THC (awaking testing) |
| CBD (avoiting testing) | CBD (awaking tesning) | CBD (owalting resting) | CED (awaiting testing) | CBD (awaiting testing) |
| TYPE: Indica Dominant Hybrid | TYPE: Bolanced Hybrid | 19PE Indica Dominant Hybrid | TYPE:Balanced Hybrid: | TVPE: Balanced Hybrid |
| GENERICS: OG Kash x Slueberry | GENETICS: Fire OG x Girl Scout Cookies | GENETICS: OG Kush x FZ Hybrid (San Fernando Vallay OG Kush x Raskals OG) | GENETICS: MK Ulora x G-13 Hoze | GENETICS: Jamaican Lambsbread x Blueberry |
| OTHER NAMES in/a | OTHER NAMES: no. | OTHER NAMES: 6/a | OTHER NAMES (of a | OTHER NAMES; rite |
| NVALLABIT ALID WINTEL | AVAILASEE MIO WINTER | AVAILABLE BIO WINTER | AVAILABLE MID WINTER | AVAILABIE MID WINTER |

Full list of strains as presented on website:

FULL WMMC PRODUCT LIST

WMMC is excited to offer the full spectrum of organically cultivated strains in the Fall & Winter of 2014.

WMMC STRAINS -

- Afghani Builrider
- Animal Cookies
- Amnesia Haze
- Blue Blood
- Blue Dream
- CBD Skunk Haze
- CBO Shark
- Durban Magic
- LSD
- Gods AK 47
- Original Strawberry Cough
- Pink Kushi
- Privilege
- Pineapple Chunk
- Purple Bubba Kush
- Sour Diesel
- Tangerine Dream
- vortex

Mettrum Ltd. - Compassionate Pricing

30/30 Mettrum Assisted Pricing Program

Mettrum is offering an assisted pricing program to help our clients obtain the medicine they need. For approved clients, Mettrum will provide a 30% discount on the first 30 grams ordered each month for Mettrum products that are 30/30 eligible*. To participate, please complete this form and send to Mettrum along with proof that you are a recipient of a Federal or Provincial income assistance program, or that you have an annual income of \$30,000 or less. Please contact Mettrum Customer Service for details on qualifying Federal or Provincial government programs. Eligibility will be approved by the Mettrum Customer Service Team during the client registration process or at any time following the receipt of your Mettrum Client Number. Once approved, the discount will be applied to your next order.

30/30 declaration form

The Peace Naturals Project Inc. - Compassionate Pricing

Does Peace Naturals Project Inc. have an Accessible Customer Service Plan?

We do. Our Accessible Customer Service Plan is available upon request. Please email info@peacematurals.com to receive a digital copy or to request for a physical copy to be mailed to you.

Tweed Inc. - Compassionate Pricing

OUR COMPASSIONATE PRICING PROMISE

Everyone's financial situation is unique, and at Tweed we understand that. This is why we're proud to offer our customers a Compassionate Pricing Promise to help you afford the medicine you need.

10%

Of Tweed production will be priced at \$5 per gram or less, including shipping pasts

20%

As part of the Compassionate Pricing Promise, a 20% discount for eligible" customers will be offered

Eligibility. In order to qualify for the 20% discount, you must submit one of the following with your registration.

- a) Proof of receipt of financial assistance from either a federal or provincial program (see list of eligible programs below), or
- b) Copy of Notice of Assessment from Canada Revenue Agency indicating your income fails below \$29,000.

Tweed knows how important your privacy is, so once we verify your documents they will be properly destroyed and not kept on file. Due to the nature of this program, Tweed retains the right to request this information on a yearly basis.

Delta 9 Bio-Tech Inc. - Compassionate Pricing

REGULAR PRICE:

This is the price per gram of a product with no quantity or compassionate pricing discounts. This price applies to all orders under 30 grams.

eg. If John's medical document allows him to purchase 1 gram/ day (30 grams/month) and John would like to order 10 grams of Product A and 10 grams of Product B (20 grams in total), his order will be regular price.

QUANTITY DISCOUNT PRICE:

This is the price per gram of a product when a minimum order of 30 grams is being fulfilled. This discount amounts to \$1 off every gram that is purchased.

eg. If John's medical document allows him to purchase 1 gram/ day (30 grams/month) and John would like to order 10 grams of Product A, 10 grams of Product B, and 10 grams of Product C (30 grams in total), his order will be assessed the quantity discount price. John will save \$30 on his order!

COMPASSIONATE PRICING PROGRAM:

At Delta 9 providing compassionate care and service to Canadians from all walks of life is a top priority. Our compassionate pricing program helps by providing patients on low income and disability a subsidy on their medicine of 50% off the regular price of any strain in our product portfolio.

Here's how it works:

Anyone can qualify for some form of financial assistance! We don't set arbitrary limits on low income because we understand that everyone's circumstances are different. The more information you can give us on what you need, the better the subsidy and the better service we can provide. In order to qualify for our Compassionate Pricing Program simply send us proof of your low income or disability. This can be in the form of proof of federal or provincial financial assistance or a copy of your Notice of Assessment from Canada Revenue Agency or other tax document that may be able to give us an idea of your individual situation.

After your information has been received our Compassionate Pricing Committee will meet to determine how we can help. The committee's decisions are based on, but not limited to, the following factors;

- The Patient's needs come first. If you qualify and need a subsidy we will provide one.
- Our company's capacity to subsidise our cannabis medicines. We're a start-up business and
 subsidising the cost of medicine can be an expensive undertaking. We will provide everyone on our
 Compassionate Pricing Program with as large a subsidy as is possible based on our ability. As our
 company grows so too will our ability to provide larger subsidies.
- The overall goal of our Compassionate Pricing Program is to do as much good for as many patients
 as possible. Subsidizing a patient's entire prescription (especially very large ones) is difficult and doing
 so would mean that we cannot help a number of other patients.

We understand how important your personal privacy is, so once your information has been considered by the committee it will be properly destroyed and not kept on file. Due to the nature of this program, Delta 9 may request information on an annual basis to continue to provide the best service. More information on our Privacy Policy can be found at http://www.deltaB.ca/privacy_policy.html.

OrganiGram Inc. - Compassionate Pricing


Do you offer any type of discount to qualified recipients of social assistance or government disability programs?

Yes, we offer a 25% discount for all orders placed by qualified patients. Qualifying is simple. We just need a copy of your most current statement from the program you are involved with and we will take care of the rest.

Bedrocan Canada Inc. - Compassionate Pricing

🗲 🖟 🗯 https://bedrocan.ca/palient-registration/patient-assistance-program/

BedroCARE Patient Assistance Program



Documents

Download Patient Assistance Program Application Form

Overview

Bedrocan Canada is offering a Patient Assistance Program to ensure that our clients can access the medicine they require. Bedrocans feel of All Patient Assistance Program is designed to help clients who have limited income entires suffer from medical disabilities by providing access to phermaceutical grade medicinels canada is.

What the Program Covers

Bedrocan will provide a 20% discount on the first 30 grams of cannable ordered within a 30 day period for select varieties of cannable (Bedio), Bedrolic and Bedrocan).

Eligibility

Clients who are burready part of a provincial or federal worker disability program, and/or social assistance program are eligible to apply. See a list of eligible programs or the hottom of this page. Single income includings or families earning less than \$20,000 annually, and disable income families earning less than \$50,000 annually may also apply.

MedReleaf Corp. - Compassionate Pricing

MedReleaf Financial Releaf.

This initiative is designed to allow patients on a low income or those living on disability to receive a 25% discount on all of our varieties.

In order to qualify, patients must apply to the program with a separate application.

Once completed, our team will evaluate each individual patient on a case-by-case basis for eligibility and patients will be notified accordingly. Please see the list below to review qualifying Federal and Provincial programs.

Compassionate Pricing Program

At MariCann we take our compassionate use program seriously. As always the patient's needs come first so please speak to our Client Service Representatives about how we can help you. To expedite the discussion please have proof of Federal or Provincial Social Assistance Program participation or Proof of Disability.

We will provide qualifying patients with a 30% discount off list price.

In order for us to be fair to all our potential customers we may have to limit some Gram per day licensees to ensure product availability for as many as possible.

This is **Exhibit "H"** referred to in the Affidavit of **TODD CAIN**Affirmed before me at the City of Ottawa, in the Province of Ontario, this 15th day of January 2015.

A Commissioner for Taking Affidavits

Sherri Laureen Szabados, a Commissioner, etc.. Province of Ontario, for the Government of Canada, Department of Health. Expires December 2, 2015



Santé Canada Your health and safety... our priority.

Votre santé et votre sécurité .. notre priorité

| STANDARD OPERATING | Controlled Substances Program | |
|--|-------------------------------|---------------------------------------|
| Conducting a Pre-Licen Marihuana for Medica | | Doc. Number: CS-SOP-021 Version: 1 |
| Bureau/Office/Area: OCS & RAPB | Status: DRAFT | Effective Date: |
| Approved by: Tier IV | | Date: XX, |



Santé Canada Your health and safety .. our priority.

Votre santé et votre sécurité . . notre priorité.

The Office of Controlled Substances ensures that precursors and controlled substances are handled effectively and remain in legal distribution channels. This involves developing legislation, regulations, policies and implementing operations that support the control of illicit drugs and other substances.

The regional Controlled Substances Program is the compliance and enforcement arm of the Office of Controlled Substances, who conducts compliance and monitoring activities to enforce the Controlled Drugs and Substances Act (CDSA) and its associated regulations including but not limited to the Precursor Control Regulations, the Narcotic Control Regulations, and the Marihuana for Medical Purposes Regulations (MMPR).

Inspectors conduct on-site inspections of regulated parties who perform activities such as importation, production and distribution of narcotics, targeted substances, restricted drugs, marihuana for medical purposes, industrial hemp, controlled drugs and precursors.

Health Canada staff work closely with both our internal partners within Health Canada and external partners including the RCMP, local law enforcement, the Canada Border Services Agency and provincial licensing bodies through joint training initiatives and other collaborative efforts.





Santé Canada Your health and safety our priority.

Votre santé et votre sécurité : notre priorité.

FOREWORD

Standard Operating Procedure (SOP) documents are meant to provide guidance to Health Canada employees on how to perform specific tasks to ensure that the requirements of all governing legislation and regulations are met. They also serve to familiarize employees with the applicable tools and record keeping methods and requirements for a specific task. SOP documents provide assistance to staff on how Health Canada mandates and objectives should be implemented in a manner that is fair, consistent, and effective.

SOP documents are administrative instruments not having force of law and, as such, allow for flexibility in approach. Alternate approaches to the principles and practices described in this document *may* be acceptable if they are supported by adequate justification and applicable legislative or regulatory requirements have been met. Alternate approaches should be discussed in advance with the relevant program area.

This document is dynamic in nature, and is offered without prejudice to future measures, which Health Canada might take in this area.

TABLE OF CONTENTS

| 1. | PURPOSE | 6 |
|------------|--|----------|
| 2. | SCOPE | 6 |
| 3. | DEFINITIONS AND ACRONYMS | |
| 3.1 | ACRONYMS | 6 |
| 3.2 | DEFINITIONS | 7 |
| 4. | ROLES AND RESPONSIBILTIES | 9 |
| 5. | BACKGROUND | 10 |
| 6. | PROCEDURE | 11 |
| 6.1 | PREPARATION AND PLANNING | |
| 6.1.1 | | 12 |
| 6.1.2 | | 13 |
| 6.1.3 | | |
| 6.2 6.3 | INTRODUCTORY MEETING | 14 |
| 6.3.1 | VERIFICATION OF REGULATORY REQUIREMENTS | 15 |
| | 1 Site Perimeter | |
| 6.3.1 | 2 Area(s) within the Site where Cannabis is Present | 10 |
| 6.3.1. | 3 STORAGE | 10 |
| 6.3.2 | Records | 10 |
| 6.3.3 | GOOD PRODUCTION PRACTICES | 19 |
| 6.3.3. | 1 Laboratory Tests | 19 |
| 6.3.3. | 2 Premises for Production, Packaging, Labelling, and Storing of Dried Marihuana | 20 |
| 6.3.3. | 3 EQUIPMENT TO PRODUCE, PACKAGE, LABEL, AND STORE DRIED MARIHUANA | 20 |
| | 4 SANITATION PROGRAM (AREAS WHERE THE DRIED MARIHUANA IS PRODUCED, PACKAGED, LABELLED, AND | |
| | 5 M | |
| 6.5.5. | 5 MATERIAL CONTROL | 21 |
| 623 | 6 PROCESS CONTROL | 22 |
| 6.3.4 | | 23 20 |
| 0.0.1 | 1 Expiry Date | |
| | 2 Samples | |
| 6.3.4. | 3 Records | 25 |
| 6.3.5 | Inventory | 2€ |
| 6.3.6 | | |
| | 1 NEW APPLICATIONS/AMENDMENT APPLICATIONS | 26 |
| 6.3.6 | | |
| 6.3.6. | | |
| 6.3.7 | | |
| 6.3.7. | | |
| 6.3.7. | 2 Records | 28 |





Santé Canada

Your health and safety. our priority.

Votre santé et votre sécurité .. notre priorité.

| 6.3.8 | Ordering | |
|----------|-------------------------------|--------------|
| 6.3.8.1 | CLIENTS | 29 |
| 6.3.8.2 | A Person other than a Client. | 29 |
| 6.3.9 | Shipping | |
| 6.3.9.1 | LABORATORY ANALYSIS | 30 |
| 6.3.9.2 | DESTRUCTION | 30 |
| 6.3.10 | RETURNS | 31 |
| 6.3.11 | RECEIVING | 31 |
| 6.3.12 | IMPORT | 31 |
| 6.3.13 | EXPORT | 32 |
| | THEFT | |
| 6.3.14.1 | AT THE SITE | 37 |
| 6.3.14.2 | In Transit | 32 |
| 6.3.15 | DESTRUCTION | 72 |
| | ADVERSE REACTIONS | |
| | RECALL | |
| 6.3.17.1 | Records | رر ۱۵ ت |
| 6.3.18 | Information Sharing | 2 <i>1</i> 2 |
| 6.4 | Exit interview | |
| 6.5 | WRITING OF REPORT | |
| | | 33 |
| 7. Ai | PPENDICES | 36 |
| | EFERENCE DOCUMENTS | |
| | UTHORS | |
| | IIMENT REVISION HISTORY | 26 |

1. PURPOSE

The purpose of this SOP is to establish a pre-defined procedure. SOPs are written instructions that are necessary to achieve and maintain a consistent approach to a process. This SOP also provides a platform for training and assessing quality.

This document aims to provide direction to Regional Managers (RM), Section Heads (SH), and Inspectors on how to conduct a Pre-Licence Inspection of a licensed producer applicant.

Inspections are conducted to monitor and verify compliance with the requirements of the *Controlled Drugs and Substances Act* (CDSA) and the *Marihuana for Medical Purposes Regulations* (MMPR). The procedures described herein are intended to ensure uniformity of action within the CSP.

This document will evolve, guided by information collected through compliance and enforcement activities conducted under the new MMPR.

2. SCOPE

This procedure applies to the inspection of applicants seeking a Marihuana for Medical Purposes Production Licence.

PLEASE NOTE:

In addition to the collection of information and verifications that reflect regulatory requirements of the MMPR, this SOP also includes related questions, considered to be best practices by Health Canada, which Inspectors may use during an inspection.

Any observation or recommendation (i.e. refusal or that a condition be included on the licence) made by the Inspector, must be clearly linked to a deficiency in a regulatory requirement and must reference the applicable section of the MMPR.

3. DEFINITIONS and ACRONYMS

3.1 Acronyms

A/RPIC Alternate Responsible Person in Charge CDSA Controlled Drugs and Substances Act CSP Controlled Substances Program

FDA Food and Drugs Act





Santé Canada Your health and safety our priority.

Votre santé et votre sécurité ... notre priorité.


FDR Food and Drug Regulations Information on the Use of Marihuana for Medical Purposes: **IUMMP** Consumer Information Sheet LPD Licences and Permits Division **MMPR** Marihuana for Medical Purposes Regulations **NCED** National Compliance and Exemption Division NCPR New Classes of Practitioners Regulations NCR Narcotic Control Regulations **PCPA** Pest Control Products Act PPE Personal Protective Equipment **RPIC** Responsible Person in Charge RM Regional Manager SOP Standard Operating Procedure Senior PIC Senior Person in Charge

Delta-9-tetrahydrocannabinol

3.2 Definitions

THC

| APPLICANT | An individual or a corporation that has submitted an application to become a licensed producer under the MMPR |
|-------------------------|--|
| AUTHORIZED PARTY | Individuals authorized under subsection 12.(4) of the MMPR to purchase or receive dried marihuana from a licensed producer |
| DESIGNATED PERSONNEL | Includes any of the following individuals: the Senior Person in Charge, the Responsible Person in Charge, or the Alternate Responsible Person(s) in Charge |
| IMMEDIATE CONTAINER | The container in direct contact with the dried marihuana |
| INSPECTOR | Any person designated as an Inspector under section 30 of the CDSA |
| LICENSED PRODUCER | The holder of a licence issued under the MMPR |





Santé Canada Your health and safety, our priority.

Votre santé et votre sécurité ... notre priorité.

PRE-LICENCE Pre-licence inspections will be conducted after an INSPECTION application has been received and a review completed. The purpose of a pre-licence inspection is to verify that the information submitted in the application is congruent with the information collected and observed on-site REGULATED Individuals authorized under subsection 12.[2] of the **PARTY** MMPR to purchase or receive marihuana; and cannabis, other than marihuana, that was obtained or produced solely for the purpose of conducting in vitro testing that is necessary to determine the percentage of cannabinoids in dried marihuana from a licensed producer SECURITY Directive on Physical Security Requirements for Controlled Substances DIRECTIVE (Security Requirements Licensed Dealers for the storage of Controlled Substances) SECURITY Guidance Document: Building and Production Security **GUIDE** Requirements for Marihuana for Medical Purposes an in-depth inspection which is not intended to assess the TARGETED INSPECTION compliance with all of the requirements of the MMPR but focuses on identified criteria TECHNICAL Guidance Document: Technical Specifications for Testing Dried Marihuana for Medical Purposes GUIDE

4. ROLES AND RESPONSIBILTIES

The planning of the inspection is a shared responsibility between the Inspector(s) and the Regional Manager (RM). The Licences and Permits Division (LPD) and the National Compliance and Exemption Division (NCED) may also provide input regarding the scheduling of inspections.

The RM is responsible for assigning an inspection team to conduct inspections and will identify a Lead Inspector. To the extent possible, Inspectors will be rotated through the inspection schedule and inspect a variety of companies. RM's are responsible for ensuring inspectors follow these procedures.

Inspectors are responsible for observing and applying procedures.

The Lead Inspector is responsible for ensuring that all aspects of the inspection are addressed.

The Lead Inspector is responsible for the overall inspection, including:

- ensuring that all information with regards to the file has been received and is available for the inspection;
- developing an inspection plan;
- coordinating all aspects of the inspection;
- assigning tasks and responsibilities amongst the team, as required;
- ensuring that inspection notes are taken by each team member according to shared responsibilities;
- acting as the spokesperson for the team;
- coordinating the writing of the report;
- organizing the exit interview;
- · recommending follow-up actions; and
- signing the inspection report and submitting it to the RM.

Within the context of an administrative inspection and the normal execution of their duties, Inspectors may review files that contain personal information. For example, inspections of licensed producer applicants and licensed producers will require Inspectors to access to records to verify that client registration and record keeping systems meet the requirements of the MMPR. There may be circumstances where in order to perform their duties (i.e., to document potential diversion of controlled substances, suspected fraudulent activities) the Inspector may need to reproduce or make note of client information, of an individual applying to be a client, or a health care professional. Under these circumstances, Inspectors should contact their





Santé Canada Your health and safety. our priority.

Votre santé et votre sécurité... notre priorité.

Section Head or Regional Manager to discuss, taking into consideration an individual's right to privacy, the appropriate approach to collecting this information for compliance management purposes.

Inspectors will only collect information as required when exercising their duties as an Inspector. Inspectors must ensure that all information is safeguarded and protected in accordance with the *Privacy Act*. Generally, Inspectors should not reproduce or make note of client information including the client's unique identifier, of an individual applying to be a client, or a health care professional. An inspection report, with the exception of an inspection report related to suspected diversion of controlled substances, fraudulent activities, serious contraventions of the regulations, must not include any information pertaining to clients, individuals applying to be clients, health care professionals or any information that could potentially identify these individuals.

5. BACKGROUND


The MMPR provides a regulatory framework whereby Canadians who are deemed to benefit from access to marihuana for medical purposes can have access to it. The MMPR replace the *Marihuana Medical Access Regulations* which will be repealed on March 31, 2014.

Health Canada plays a role in protecting the health of Canadians who are prescribed marihuana for medical purposes, by ensuring they receive the medication deemed necessary. A second objective is to ensure the supply of marihuana for these Canadians meets their prescribed requirements. Health Canada is a regulatory department, and C&E activities are essential to the success of regulatory activities.

The operational framework and strategic direction for C&E activities to be conducted under the MMPR are set out in CS-OF-001 Operational Framework for Compliance and Enforcement Activities for the Marihuana for Medical Purposes Regulations (MMPR), CS-POL-001 CDSA Compliance and Enforcement Policy, and CS-GD-010 MMPR Compliance Management and Endpoints.

The role of Inspectors includes performing site inspections, providing compliance promotion, communicating with LPs and LP applicants, and conducting monitoring and enforcement activities.

Section 30 of the CDSA covers the designation of Inspectors and their duty to identify themselves when entering a place under the authority of this Act.





Santé Canada Your health and safety...our priority.

Votre santé et votre sécurité notre priorité.

Section 31 of the CDSA describes the places an Inspector may enter, the powers granted to them, and the use of computers and copying equipment in carrying out an inspection. Subsection 31.(2) of the CDSA covers the entry into a dwelling-place and the conditions attached to that activity.

Section 9 of the MMPR authorizes inspections to be conducted to confirm information submitted in support of an application, amendment or renewal of a licence.

5.1 Resources and Equipment

During an inspection, each Inspector must carry their badge and inspector identification card, and must use PPE as required. In addition the following materials may be useful:


- Inspection plan
- Notebook and pens
- · Cellular phone
- · Measuring tape
- Business cards
- CSP/ OCS telephone contact list
- MMPR PLI Questionnaire
- Sample Medical Document for the MMPR

- MMPR
- IUMMP
- NCR and NCPR
- CDSA and FDA Schedule B
- · Security Directive
- Security Guide
- Technical Guide
- Industrial Hemp Technical Manual Standard Operating Procedures for Sampling, Testing and Processing Methodology

6. PROCEDURE

A Pre-Licence Inspection is an inspection to verify that the information submitted to Health Canada is accurate and to assess compliance with the applicable sections of the MMPR prior to licence approval.

Unlike other inspections, pre-licence inspections are announced. The inspection should be announced a few days in advance. As a courtesy, arrangements will be made with the proposed Senior PIC to make sure that they and the proposed RPIC are available and, if possible, the proposed A/RPIC(s). It is preferable that both the proposed Senior PIC and RPIC be present during the inspection.





Santé Canada Your health and safety our priority.

Votre santé et votre sécurité notre priorité.

The on-site portion of a pre-licence inspection should be completed within one (1) day. The number of Inspectors assigned to complete a pre-licence inspection will be determined by the RM.

6.1 Preparation and Planning

This phase of the inspection consists of three main tasks: gathering information, reviewing documentation, and creating the inspection plan.

The Inspector should contact the applicant and confirm whether there are any plants currently on the site. If there are plants, the Inspector should verify the number of plants on site and under which licence(s) number(s) they are authorized. The Inspector should identify the presence of plants on the site to the RM.


Also, the Inspector should discuss with the applicant what PPE they require at the site and, if applicable, any procedures they have in place to protect the health and safety of their employees. It is the responsibility of each Inspector to have the appropriate PPE with them prior to arriving at the site.

6.1.1 Pre-Inspection Information Gathering

The RM will determine whether a detailed assessment of risks to personal safety is required. This determination will include the following factors:

- whether the applicant has successfully completed the required criminal record checks, and whether those checks reveal offences that give rise to personal safety concerns;
- whether the applicant has successfully obtained the required security clearances, and whether the required security clearances are substantially delayed;
- the compliance history of the applicant, if applicable; and
- information previously received from law enforcement regarding the applicant.

It is the RM's responsibility to conduct and document a risk assessment where one is required. When a PLI is requested by OCS, the applicant will either have all the security clearances in place or OCS will have contacted and had the inspection approved by DSO, therefore no additional information can be provided by OCS. If deemed necessary, the RM may contact the appropriate RCMP regional coordinator notified of the application by the applicant, to ask whether they believe there would





Santé Canada Your health and safety... our priority.

Votre santé et votre sécurité .. notre priorité.

be an occupational health and safety risk to the inspection team upon attending the site. The information that the RM may share with the RCMP, or any local police or local enforcement, is limited to the site address and the name of the Senior PIC. The RM will allow at least 48 hours for a response.

If concerns relating to personnel safety are identified in the course of the risk assessment, the RM will determine, in consultation with the Departmental Security Officer and the inspection team, what measures should be taken to mitigate the risks. Please refer to CS-SOP-016 Safety and Security of Inspectors.

6.1.2 Pre-inspection Document Review

The Inspectors will examine the company file and any other pertinent information, including the following information:

- licensed producer application;
- list of proposed designated personnel;
- description of the proposed security measures and internal controls (i.e. record keeping, good production practices, quality assurance);
- any pertinent correspondence; and
- any inspection reports or correspondence if previously licensed or if other sites of the same company were licensed.


After reviewing the file, the Inspector will identify any safety concerns. If serious concerns are noted, police accompaniment should be discussed with the RM.

6.1.3 Preparing the Inspection Plan

The MMPR Pre-Licence Inspection Questionnaire (MMPR PLI Questionnaire) should be used as a reference tool to structure and plan the inspection. Modification to the inspection plan may be required once the Inspector is on the premises.

The inspection plan should identify:

- the purpose of the inspection;
- the security measures and internal controls to be verified;
- the designated personnel information;
- the activities and documents to be verified;
- PPE required; and
- in cases involving an inspection team, the role of each inspector.



6.2 Introductory Meeting

Upon arriving at the proposed licensed site, the Inspectors will introduce themselves and present their identification cards. The Inspectors will not allow anyone to handle their identification cards.

The Inspectors will confirm the site is not a dwelling-place and whether there is more than one building at the site. If the site is a dwelling-place the Inspectors should contact the RM immediately.

The Inspectors will then present their business cards and request to speak with one of the proposed designated personnel.

The Inspectors will identify themselves to the proposed designated personnel as above.

The Inspectors will hold a <u>brief</u> meeting with the available proposed designated personnel to explain the purpose of the inspection and under what statute and regulations it is being conducted. The names and titles of all individuals attending the meeting will be documented. CS-FRM-XXX may be used to record attendance.

The following should be accomplished during the introductory meeting:

- General information on how the inspection will be conducted should be provided to company personnel.
- The list of the proposed designated personnel and other personnel should be verified including their names, titles, contact information, and hours of work.
- The civic address of the site should be verified. Confirm the site is not a dwellingplace and if there is more than one building at the site. If the site is a dwellingplace the Inspector should contact the RM immediately.
- Confirm if there are any co-existing entities that operate within the site.
- The overall hours of operation of the facility (including office area, production area, storage area, shipping/receiving area, etc.) should be verified.
- The information (proposed activities and substances) on the applicant's licensed producer application should be confirmed.
- The geographical area that the applicant intends to provide service to should be confirmed.
- The expected clientele should be confirmed.
- A site/floor plan should be requested, if not included in the file.
- Re-confirm whether plants are present on the site and identify their storage location(s) on the site/floor plan.





Santé Canada Your health and safety... our priority.

Votre santé et votre sécurité... notre priorité.

- If the applicant is in apparent violation of their Marihuana Medical Access Regulations licence(s), the Inspector should note all compliance related issues in their note book and advise the RM when convenient.
- If the applicant had originally identified there would be no plants present at the site and upon arriving at the site the Inspector becomes aware of plants being present, they should contact the RM immediately.
- A sample of an inventory report should be requested.
- Discuss potential personal health and safety concerns found at the site and reconfirm with the applicant the PPE required at the site and, if applicable, any health and safety procedures that must be followed.
- Confirm the last time that pesticides were applied or when a treatment was applied to deal with any pests at the facility (pest control within the facility and/or for the plants).

6.3 Verification of Regulatory Requirements

Inspectors will perform the following actions and note any discrepancies between observed practices and records, and the applicant's submission to OCS. In addition, the Inspectors will document any opportunities for diversion and assess the security measures for effectiveness and sufficiency.


If records are not available because no production for any type of product is taking place, request to see the proposed record keeping system the applicant intends to put in place.

PLEASE NOTE:

The MMPR PLI Questionnaire should be used as a reference tool only and should not be systematically filled with the designated personnel at any point during the inspection. The Inspector can refer to it at any time to make sure all aspects of a specific activity have been covered or to identify additional questions to ask in order to ensure that all required documentation and information has been obtained.

6.3.1 Security

 Visually inspect and confirm the accuracy of the floor plan submitted with the application or provided at the time of the inspection and record the location of the areas within the site where cannabis is present, the ventilation, and the flow of material through the site.




6.3.1.1 Site Perimeter

- Review with the applicant how the design of the perimeter of the site prevents unauthorized access.
- Confirm that an appropriate system will be in place to control the distribution of the codes, keys, and other elements of the security system.
- Confirm if the perimeter of the building has any physical barriers or signage posted at the perimeter and entrances to prevent unauthorized access.
- Confirm the number of entranceways to the site.
- Confirm how the entranceway(s) are secured to prevent unauthorized access.
- Confirm if openings, ducts, and pass-throughs are covered with security screens, steel bars, or equivalent material, welded to steel frames to assist in preventing unauthorized access.
- Confirm the construction of the walls at the site.
- Assess the perimeter of the site to ensure that there are sufficient visual recording devices to visually monitor it at all times in order to detect attempted or actual unauthorized access.
- Assess whether the visual recording devices, in the conditions under which they are used, are capable of recording in a visible manner any attempted or actual unauthorized access.
- Confirm the visual recordings from the perimeter of the site will be maintained for two years.
- Confirm that the intrusion detection system will operate and be monitored at all times.
- Assess/test the intrusion detection system that will be used to detect:
 - attempted or actual unauthorized access to, or
 - o movement around the perimeter, or
 - o tampering with the system.
- Review with the applicant the steps to be taken by the monitoring personnel in response to any detected activity that is unauthorized.
- Confirm that the monitoring personnel will record the required information if any unauthorized activity is detected.
- Confirm records created by the monitoring personnel for any detected unauthorized activity from the perimeter of the site will be maintained for two years.

6.3.1.2 Area(s) within the Site where Cannabis is Present

• Confirm how access to area(s) within the site where cannabis is present (referred to in this section (6.6.1.2) as "those area(s)") will be restricted to





Santé Canada Your health and safety...our priority.

Votre santé et votre sécurité : notre priorité.

persons whose presence in those area(s) is required by their work responsibilities.

- Confirm that the RPIC or A/RPIC, if applicable, will be physically present while other persons are in those area(s).
- Confirm that an appropriate system will be in place to control the distribution of the codes, keys, and other elements of the security system.
- Review the process and/or system that the applicant intends to use to capture the name of every person entering or exiting those area(s).
- Confirm if those area(s) have any physical barriers or signage posted to prevent unauthorized access.
- Confirm the number of entranceways to those area(s).
- Confirm how the entranceway(s) are secured to prevent unauthorized access.
- Confirm if openings, ducts, and pass-throughs are covered with security screens, steel bars, or equivalent material, welded to steel frames to assist in preventing unauthorized access to the area(s).
- Confirm the construction of the walls in the area(s).
- Confirm if glazed panels will be used in any of the area(s).
- If glazed panels are used, confirm that appropriate electronic equipment is being used to monitor the glazing elements, including sensors that can detect breakage of glazing panels.
- Assess if there are sufficient visual recording devices to visually monitor the area(s) at all times to detect illicit conduct.
- Assess whether the visual recording devices, in the conditions under which they are used, are capable of recording in a visible manner illicit conduct.
- Confirm the visual recordings from the area(s) within the site where cannabis is present will be maintained for two years.
- Assess/test the intrusion detection system that will be used to detect:
 - o attempted or actual unauthorized access to, or
 - o movement in the area(s), or
 - o tampering with the system.
- Confirm that the intrusion detection system will operate and be monitored at all times.
- Review with the applicant the steps to be taken by the monitoring personnel in response to any detected activity that is unauthorized.
- Confirm that the monitoring personnel will record the required information if any unauthorized activity is detected.
- Confirm records created by the monitoring personnel for any detected unauthorized activity from the area(s) within the site where cannabis is present will be maintained for two years.
- Confirm those area(s) have a system in place that will filter air to prevent the escape of odour and, if present, pollen.





Santé Canada Your health and safety .. our priority.

Votre santé et votre sécurité ... notre priorité.

6.3.1.3 Storage

PLEASE NOTE:

These additional requirements apply to the storage of controlled substances which includes dried marihuana, marihuana seeds and cannabis used solely for the purpose of testing in order to determine the percentage of cannabinoids in dried marihuana (both packaged and unpackaged). These requirements also apply to all waste cannabis material from cultivation or production with the exception of mature cannabis stalks that do not include leaves, flowers, branches or seeds; and fibers derived from the stalks, as well as, any non-viable cannabis seeds. Additionally, these requirements do not apply to plants or cannabis material undergoing the drying process.

- Review with the applicant how the design of the storage location(s) prevent(s) unauthorized access.
- Confirm that only persons whose presence is required by their work responsibilities have access to the vault/safe or cage.
- Confirm that an appropriate system will be in place to control the distribution of the codes, keys, combination, and other elements of the security system.
- Verify that the applicant will calculate the illicit value of cannabis in their possession on a regular basis to ensure that they do not exceed the approved security level as indicated on their licence.
- Verify that only controlled substances will be kept in these areas.
- Confirm the in-house laboratory, if applicable, will keep the reference standards and samples stored as required by the Security Directive.
- Confirm that the RPIC or A/RPIC, if applicable, will be physically present while other persons are handling controlled substances.
- Confirm that only the qualified person in charge (i.e., RPIC, A/RPIC) should have the authorization to disarm a vault/safe or cage.
- Confirm that only the qualified person in charge (i.e., the RPIC, A/RPIC) will have the key to the cage and the combination for the safe/vault.
- Verify the storage conditions (vault or safe and cage, if applicable) against the measures submitted and the Security Directive.
- Verify that the combination will be changed at regular intervals (at least once a year) and/or when a person having the combination is no longer a designated RPIC or A/RPIC.
- Conduct an alarm test of the intrusion detection devices and system required by the Security Directive.
- If an expiry date will be assigned to a product confirm that the product will be stored under the recommended storage condition for that expiry date.



Your health and safety .. our priority.

Votre santé et votre sécurité : notre priorité.

6.3.2 Records

- Confirm that the record keeping system permits an audit to take place in a timely manner.
- Assess whether the record keeping system permits the reconciliation of receipts, production, orders, shipments, and cannabis inventory.
- Confirm that the required records will be available at the site.

6.3.3 Good Production Practices

PLEASE NOTE:

These items will be confirmed for compliance education and promotion purposes. However any indication that the issuance of the licence would create a risk to public health, safety or security must be detailed in the inspection report.

- Confirm the SOP(s) that will be implemented at the site regarding the production, packaging, labelling, and storage of the dried marihuana.
- Confirm that the SOP(s) are designed to ensure that the above activities are conducted in accordance with the Good Production Practices of the MMPR.
- Confirm how the applicant intends to obtain uniformity of THC and cannabidiol content in the material provided to its clients.
- Confirm the applicant has developed a sampling plan to confirm uniformity of THC and cannabidiol content of the finished products.
- Confirm how the applicant intends to control microbial and chemical contaminants.

6.3.3.1 Laboratory Tests

- Establish whether all laboratory tests will be conducted in house or through an external laboratory.
- Confirm that the applicant will establish its acceptable tolerance limits for herbal medicines for human consumption (referred to in Schedule B to the FDA) for microbial and chemical contaminants of the dried marihuana.
- Confirm a validated methodology will be established to determine the microbial and chemical contaminants.
- Confirm a validated methodology will be established to determine the THC and cannabidiol content of the cannabis (including dried marihuana).





Santé Canada Your health and safety, our priority

Votre santé et votre sécurité notre priorité.

- Confirm that the applicant will establish its acceptable tolerance limits for THC and cannabidiol.
- Confirm that marihuana will not be treated before, during, or after the drying process with a pest control product that has not been registered under the PCPA for use on marihuana for medical purposes.
- Confirm that the applicant will determine its maximum residue limit(s) specified for its pesticide control product(s).
- Confirm a validated methodology will be established to determine the pesticide control product residues.
- Confirm that if an expiry date is assigned to a product how the applicant intends to ensure that the dried marihuana maintains not less than 80% and not more than 120% of the percentage of THC weight per weight and cannabidiol weight per weight as indicated on the label.
- Confirm that if an expiry date is assigned to a product, how the applicant will
 ensure that the microbial and chemical content of the dried marihuana
 remains within the acceptable limits.
- 6.3.3.2 Premises for Production, Packaging, Labelling, and Storing of Dried Marihuana
- Confirm the following:
 - areas permit those activities to be conducted under sanitary conditions.
 - o areas are clean and orderly
 - o design of the areas enables the effective cleaning of all surfaces in the premises
 - o dried marihuana is stored and processed appropriately
 - o area prevents the contamination of the dried marihuana
 - o area prevents the addition of an extraneous substance to the dried marihuana
 - o storage conditions of the dried marihuana maintain the product's quality
- 6.3.3.3 Equipment to Produce, Package, Label, and Store Dried Marihuana
- Confirm the equipment is designed, constructed, maintained, operated and arranged in a manner that:
 - o permits the effective cleaning of its surfaces
 - o permits it to function in accordance with its use
 - o prevents it from contaminating the dried marihuana
 - o prevents it from adding extraneous substance to the dried marihuana



Santé Canada Your health and safety... our priority

Votre santé et votre sécurité : notre priorité.

6.3.3.4 Sanitation Program (Areas where the Dried Marihuana is Produced, Packaged, Labelled, and Stored)

- Review and confirm that a sanitation program will be implemented for the areas used to produce, package, label and store the dried marihuana.
- Confirm the following:
- The program will ensure that the premises in which the above activities are conducted will be effectively cleaned.
- The program will ensure that the equipment used in the above activities will be effectively cleaned.
- The program will ensure that the handling of the dried marihuana is conducted in sanitary conditions.
- The program will ensure that all requirements in regards to health are met (i.e. hygienic behaviour of the personnel who are involved in the above activities and the cleanliness of their clothing, etc.) to ensure that the above activities are conducted in sanitary conditions.
- There is a pest control program in place, delivered by an external contractor licensed to perform that function and that written reports are being provided by the contractor.

6.3.3.5 Material Control

- Confirm that the applicant will set up and follow written procedures for the transportation, receipt, identification, examination, handling, sampling, testing and approval or rejection of raw and/or packaging materials.
- Confirm each lot of raw and/or packaging materials will be assigned a distinctive lot number.
- Confirm that containers of raw and/or packaging materials will be inspected upon receipt for closure and physical integrity.
- Confirm each lot of raw and/or packaging materials will be assessed against specifications, such as plant identity, detectable foreign matter and the integrity (appropriate characteristics) and quality of plant material.
- Confirm raw and/or packaging materials will be retested after any exposure to conditions likely to adversely affect their purity, quality or composition.
- Confirm each lot of raw and/or packaging materials will be identified and controlled according to its quality status (i.e. quarantined, approved or rejected).
- Confirm that raw materials, in-process materials and reprocessed materials will be stored in appropriate conditions, including temperature and humidity, to protect against quality deterioration and contamination.





Santé Canada Your health and safety... our priority.

Votre santé et votre sécurité : notre priorité.

- Confirm that time limits will be established beyond which raw materials that are subject to deterioration may not be used without additional testing.
- Confirm outdated or obsolete printed packaging materials will be destroyed and a record of the disposal will be made.
- Confirm that appropriate systems and controls will be established to ensure
 water used to produce products is of potable quality and meets the WHO
 guidelines for Drinking Water Quality or other standards, as well as the
 Guidelines for Canadian Drinking Water Quality [see http://www.hc-sc.gc.ca/ewh-semt/water-eau/drink-potab/guide/index e.html]

6.3.3.6 Process Control

- Confirm the growth of the cannabis will ensure that it adheres to regulatory requirements.
- Confirm a master production document will be prepared for the production of each product, and that the quality assurance person will review and approve the document.
- Confirm that batch records for each batch of product will be prepared and followed.
- Confirm each batch of product produced will be allocated an individual control number that can be tracked.
- Confirm any deviations from written and approved production processes, standards and test methods, will be recorded and evaluated with the final approval given by the person in charge of production as well as the quality assurance person.
- Confirm that the production, packaging and storage operations will be conducted according to written procedures and appropriate sanitation principles, in a manner that protects against adulteration and in conditions that minimize the potential for contamination.
- Confirm that all materials, products, samples, containers, processing lines and major equipment will be identified at all times to indicate their contents and/or status.
- Confirm procedures will be in place to prevent extraneous materials from being included in the products and finished package.
- Confirm procedures will be in place to identify, store and dispose of rejected or contaminated/adulterated products.
- Confirm written procedures will be established for reprocessing batches that do not conform to finished product specifications.
- Confirm labels are securely stored to prevent mix-ups (i.e. stored and withdrawn against a packaging order).





Santé Canada Your health and safety... our priority.

Votre santé et votre sécurité ... notre priorité.

- Confirm cross-contamination and mislabelling will be prevented by establishing procedures for removing all raw and/or packaging materials and finished products from previous runs (i.e. written line clearance procedures).
- Confirm written procedures will be set up and followed to ensure the correct labels and packaging materials are issued and used.
- Confirm each package will be identified with a lot number and expiry date, if applicable.
- Confirm written procedures will be set up and followed for preparing samples of raw material, in-process materials and finished products, including the conditions of their storage and the duration of such storage.
- Confirm that on completion of each stage of processing, the equipment and containers used during critical in-process stages will be labelled (i.e. unique reference number, name, batch or lot number, batch or lot size, storage conditions, date of preparation, person responsible for the processing).

6.3.3.7 Records


- Confirm that a copy of the SOP(s) in use at the site will be maintained on site.
- Confirm training records will be maintained for staff which will include the training content covered and completion dates.
- Confirm the records that will be created will demonstrate that each batch has been produced, packaged and labelled according to the procedures described in the master production document.
- Confirm the applicant will maintain a list of all brand names of the dried marihuana they produce.

6.3.4 Quality Assurance

PLEASE NOTE:

This section applies to the finished products (which must be followed at all stages of production, packaging, labelling, and storage of the dried marihuana) as well as to any imported marihuana when it is to be sold or provided in Canada, and to any Canadian-produced marihuana which is to be exported.

- Confirm who will be the quality assurance person on site.
- Review the description of the qualifications of the quality assurance person.
- Confirm that all personnel will have the appropriate education (including ongoing Good Production Practices (GPP) or other continuing training) and/or have the practical experience necessary to perform their assigned duties.
- Confirm written specifications for all finished products will be developed and will be implemented.





Santé Canada Your health and safety our priority.

Votre santé et votre sécurité notre priorité.

- Confirm the specifications will be maintained and every change will be approved by the quality assurance person prior to use.
- Confirm written procedures will be developed and will be followed that
 describe the tests to be conducted and that all test methods will provide
 accurate and consistent results.
- Confirm the applicant and any external laboratory will have a technical agreement covering the arranged tests they will perform on behalf of the applicant.
- Confirm written procedures will be established and followed to ensure that the products will conform to the specifications and regulatory requirements.
- Confirm written procedures will be established and followed for sampling, inspecting, and testing raw materials, in-process, and finished products.
- Confirm that the quality assurance person will approve and release or reject all raw materials, packaging materials and finished products, based upon conformance/non-conformance to respective specifications prior to its use.
- Confirm that the quality assurance person will approve or reject all procedures, specifications, test methods, controls and results that affect the purity, quality and composition of the product.
- Confirm that the quality assurance person will review and maintain completed batch records.
- Confirm that the quality assurance person will ensure that laboratories (inhouse and/or contract) are capable of performing all of the tasks and responsibilities assigned to them.
- Confirm that every lot or batch of dried marihuana will be tested for microbial and chemical contaminants as required by the Pharmacopeia selected from Schedule B to the FDA, as well as, for the THC and cannabidiol levels, and any pesticide residues, if applicable.
- Confirm a visual inspection of the dried marihuana will take place to confirm the absence of pests or extraneous substances (i.e. any material or substance other than dried marihuana).
- Confirm that every lot or batch of dried marihuana will be approved by the quality assurance person prior to its sale based on its completed batch records and test results.
- Confirm written procedures will be established and followed to approve or reject product quality deviations and product reprocessing.
- Confirm a process will be developed to record every complaint received regarding the quality of the dried marihuana and whether any further investigations and/or corrective action will be required.
- Confirm dried marihuana returned from authorized parties will not be resold or provided again.
- Confirm written procedures have been established and will be followed to handle the destruction of returned products.





Santé Canada Your health and safety our priority.

Votre santé et votre sécurité : notre priorité.

- Confirm written procedures will be reviewed regularly and will be kept up-todate.
- Confirm there will be a system for revising the procedures and the reason for any revisions will be documented.
- Confirm the system will ensure that only current procedures are in use.

6.3.4.1 Expiry Date


- Confirm if the applicant intends to provide an expiry date for their products.
- Confirm if accelerated or real-time stability studies will be used to make an initial determination of the expiry date.
- Confirm the data and rationale will be provided to the OCS to reasonably ensure that the expiry date is appropriate.
- Confirm the expiry date will be adjusted, when required, on the basis of realtime studies on product stored in the conditions noted on the label, for the period of time indicated by the expiry date.
- Confirm the product shelf-life will be re-evaluated when significant changes are made to the process or package that may affect the product's stability.

6.3.4.2 Samples

- Confirm that samples of each batch or lot will be maintained for at least one year after the date of the last sale or provision of any portion of the lot or batch of dried marihuana.
- Confirm that the retention samples will be in sufficient quantities that would enable the Minister to make a determination of whether the lot or batch of dried marihuana meets the requirements of the laboratory tests.
- Confirm the retained samples will be maintained in their final trade packages or in containers of the same material and construction.
- Confirm the retained samples will be stored in the environmental conditions listed on the label.

6.3.4.3 Records

- Review the documentation, if available, that will be used to capture the approval of the dried marihuana by the quality assurance person prior to its sale.
- Confirm the quality assurance person will maintain all laboratory records of tests and investigations.
- Confirm that all written procedures will have evidence of their approval for use by the quality assurance person.





Santé Canada Your health and safety .. our priority.

Votre santé et votre sécurité... notre priorité.

- Confirm the quality assurance person will maintain all records of complaints with the following information: the name and description of the product, the lot number, the source and nature of the complaint, and any response. When an investigation is conducted, confirm that the quality assurance person will include in the written record the findings and any follow-up action taken.
- Confirm that records with respect to returned products will be maintained and will include the name and description of the product, lot number, reason for return, quantity returned and date and means of final disposition. Please refer to the sections 20, 145, and 148 of the MMPR for the complete description of the requirements that must be met and records that must be made to destroy cannabis.
- Confirm that the applicant will have a means of recording the retention samples that will be maintained at the site.
- Confirm authorized written procedures for all sections of these requirements will be retained for reference and inspection.

6.3.5 Inventory

- Confirm that a record of the net weight of the following material identified in section 146 of the MMPR will be made at the end of each quarter of the calendar year:
 - Marihuana seeds;
 - Harvested marihuana in respect of which the drying process has not been completed, other that marihuana that is destined for destruction or packages;
 - Harvested marihuana in respect of which the drying process has been completed, other than marihuana is destined for destruction or packages;
 - Marihuana that is destined for destruction;
 - o Packaged marihuana; and
 - Cannabis other than marihuana, specifying the name and net weight of each of the substances in questions.

6.3.6 Registration

6.3.6.1 New Applications/Amendment Applications

- Confirm the applicant will have a process and/or system in place to register its clients.
- Ensure that all of the required information is being collected as per section 108, subsections 109.(1) and (4), and section 115 of the MMPR.





Santé Canada Your health and safety .. our priority.

Votre santé et votre sécurité notre priorité

- Confirm the applicant will have a process and/or system in place to ensure that all of the elements in section 110 of the MMPR are met prior to registering a client.
- Confirm the applicant will have a process and/or system in place to notify clients in writing when they have been registered. Ensure that all of the information required under subsection 111.(2) and section 116 of the MMPR is captured.
- Confirm each client will receive a unique identifier.
- Confirm each registration will be assigned an expiry date.
- Confirm that the process and/or system will have a means of preventing a client from placing an order and receiving an order of dried marihuana after their registration has expired.

6.3.6.2 Refusals

- Confirm the applicant will have a process and/or system in place to assess applications and determine if they should refuse to amend a registration of an existing client or to register the potential client.
- Confirm the applicant will have a process and/or system in place to notify clients or potential clients in writing that the applicant is proposing to refuse to register them as a client.
- Confirm the applicant will have a process and/or system in place to assess the response provided by the client or potential client and the reason(s) why the applicant's decision to refuse to register them is unfounded.
- Confirm the applicant will have a process and/or system in place to return the medical document without delay to the clients or potential clients they refuse to register.

6.3.6.3 Cancellation

- Confirm the applicant will have a process and/or system in place to assess the situation and determine if a registration should be cancelled.
- Confirm the applicant will have a process and/or system in place to notify clients in writing that their registration has been cancelled.
- Confirm the applicant will have a process and/or system in place to assess the response provided by the client and the reason(s) why the applicant's decision to cancel their registration is unfounded.
- Confirm that the applicant will not return any medical document to a client whose registration has been cancelled.



Votre santé et votre sécurité .. notre priorité.

6.3.7 Packaging

- Confirm the packaging that the applicant intends to use.
- Confirm the immediate container has a security feature that provides reasonable assurance to the consumers that the container has not been opened prior to receipt.
- Confirm that the immediate container is a child resistant package that meets the requirements of subsections C.01.001.(2) to (4) of the FDR.
- Confirm the process and/or system the applicant intends to implement will ensure that no more than 30g of dried marihuana is in the immediate container.
- Confirm the process and/or system the applicant will have in place to ensure that the immediate container does not contain less than 95% and not more than 101% of the net weight as specified on the label.
- Confirm the applicant will maintain a list of all brand names of the dried marihuana they package.
- Confirm that the product will be kept dry and free from contamination until the expiry date (i.e. deterioration of packaging material and labelling), if applicable.
- Confirm if the immediate container will be washed and dried before use.

6.3.7.1 Labelling

- Review the proposed immediate container label(s) to ensure that it meets all of the requirements laid out in sections 66, 67, 68, and 70 of the MMPR.
- If a combined label is used, confirm that criteria set out in s. 66 and paragraph 67(a) of the MMPR will be met.
- Confirm with the applicant if they intend to include an expiry date on the immediate container label. Verify that if an expiry date will be included that the LP plans to submit data to the Minister that establishes the stability period as required by the regulations.
- Confirm the applicant will maintain a list of all brand names of the dried marihuana they label.

6.3.7.2 Records

• Confirm the applicant will maintain evidence or records of packaging material testing that was conducted with respect to the material used to package the finished product dried marihuana.





Santé Canada Your health and safety .. our priority.

Votre santé et votre sécurité... notre priorité.

6.3.8 Ordering

6.3.8.1 Clients

- Confirm that each order (written or verbal) will contain all of the required information as per subsection 121.(2) and section 137 of the MMPR.
- Confirm that the applicant will make a record of the information required under subsection 138.(1) of the MMPR for each order received.
- Confirm the applicant will have a process and/or system in place to assess orders and determine if an order should be refused to be filled.
- Confirm the applicant will have a process and/or system in place to notify clients in writing that the applicant is refusing to fill an order.
- Confirm the applicant will have a process and/or system in place to prevent a
 client or the individual responsible for that client from being sold or provided
 with a total quantity of dried marihuana that exceeds 30 times their daily
 quantity in any 30-day period.

6.3.8.2 A Person other than a Client

PLEASE NOTE:

This section is referring to authorized parties (specifically hospital employees and section 56 exemption holders) and regulated parties.

- Confirm that before filling any written order the applicant will verify that it contains all of the required information as per subsection 131.(3) of the MMPR.
- Confirm the applicant will have a process and/or system in place to assess the orders and determine if an order should be refused to be filled.
- Confirm that the applicant will make a record of the information required under subsection 140.(1) for any order filled.
- Confirm the applicant will have a process and/or system in place to notify the person placing the order in writing that the applicant is refusing to fill an order.

6.3.9 Shipping

• Confirm how the applicant intends to ensure the safe keeping of the cannabis (including dried marihuana) during its shipping, delivery, or transportation.

Review the shipping process and/or system the applicant intends to implement.



Your health and safety our priority.

Votre santé et votre sécurité .. notre priorité.


- Confirm that each shipment of dried marihuana to a client or an individual who is responsible for that client will contain the following document in English and French:
 - A separate document that will include the same information captured under subsection 67.(a) of the MMPR.
- Confirm that each shipment of dried marihuana to an authorized party will contain the following document in English and French:
 - The document entitled "Information on the Use of Marihuana for Medical Purposes".
- Confirm that the applicant has a process and/or system in place that ensures an
 authorized party, another licensed producer, a licensed dealer, the Minister, or a
 holder of a section 56 exemption is shipped marihuana in only one shipment per
 order.
- Confirm that the applicant will be using a shipping method that will allow the package (cannabis including dried marihuana) to be tracked during transit and will ensure its safekeeping during transit.
- Confirm that any package of dried marihuana shipping to an authorized party, another licensed producer, a licensed dealer, the Minister, or a holder of a section 56 exemption:
 - Will not open or permit the escape of its contents during handling and transportation.
 - o It is sealed so that it cannot be opened without breaking the seal.
 - o It prevents the escape of marihuana odour.
 - o It prevents the contents from being identified without it being opened.
- Confirm that an order for cannabis from another licensed producer, a licensed dealer, the Minister, or a holder of a section 56 exemption is only shipped to the address found on the written order (section 131 of the MMPR).

6.3.9.1 Laboratory Analysis

- Review the shipping process and/or system the applicant intends to implement with regards sending samples of cannabis for analysis to an external laboratory, if applicable.
- Confirm that the external laboratory will have a controlled substance licence to conduct activities with cannabis.

6.3.9.2 Destruction

 Review the shipping process and/or system the applicant intends to implement with regards to destruction at a location other than the licensed site.



Votre santé et votre sécurité... notre priorité.

6.3.10 Returns


- Confirm if the applicant will accept returns.
- If the applicant will accept returns, confirm that they will have a process and/or system in place to handle returns of dried marihuana.
- Confirm that applicant will make a record of the information required under section 139 of the MMPR for any dried marihuana returned to the applicant.
- Review the shipping process and/or system the applicant intends to implement with regards to returns from their clientele.

6.3.11 Receiving

- Confirm the applicant will have a process and/or system in place to receive cannabis from a licensed producer or a licensed dealer.
- Confirm the applicant will have a process and/or system in place to receive dried marihuana from a client or the individual responsible for that client, if returns are accepted.
- Confirm the applicant will make a record of the information required under section 134 of the MMPR for any cannabis received by the applicant.

6.3.12 Import

- Confirm whether the applicant intends to import marihuana.
- If the applicant intends to import marihuana, confirm that the applicant is aware of their responsibilities as a licensed producer to:
 - apply for and obtain an import permit to be able to import marihuana into Canada
 - provide the customs office, sufferance warehouse or bonded warehouse a copy of the permit at the port of entry into Canada at the time of importation, upon request of the customs officer
 - o ensure that, after the imported marihuana clears customs, it is transported directly to the proposed site
 - provide the Minister with a declaration confirming the importation within
 15 days after the day of release from customs. The information that must
 be included in the declaration is under section 78 of the MMPR
 - o that they may not import marihuana for the purpose of re-exporting it
- If the applicant intends to import marihuana, confirm that the applicant is aware that they are prohibited from re-exporting the imported product.



Your health and safety our priority.

Votre santé et votre sécurité... notre priorité.

6.3.13 Export

- Confirm whether the applicant intends to export marihuana.
- If the applicant intends to export marihuana, confirm that the applicant aware of their responsibilities as a licensed producer to:
 - o apply for and obtain an export permit to be able to export marihuana from Canada
 - provide the customs office, sufferance warehouse or bonded warehouse a copy of the permit at the port of exit from Canada at the time of exportation, upon request of the customs officer
 - provide the Minister with a declaration confirming the exportation as per section 86 of the MMPR, within 15 days after the day on which the shipment is exported

6.3.14 Theft

6.3.14.1 At the Site

- Review with the applicant the process or verification steps that will be in place to indicate/identify a theft of cannabis (including dried marihuana) or an unusual waste or disappearance of cannabis that cannot be explained on the basis of normal accepted business activities.
- Confirm with the applicant the quantity of material they could consider as an unusual waste or disappearance.
- Determine whether the applicant will have an SOP in place to describe the process that must be followed to confirm an unusual waste or disappearance.
- Confirm the identification of the person, within the organization, who will be responsible for investigating any unusual waste or disappearance.
- Confirm the identification of the person, within the organization, who will be responsible for advising the police and the Minister of an unusual waste or disappearance.

6.3.14.2 In Transit

- Review the process that will be used to address a loss or theft of cannabis (including dried marihuana) during transit.
- Determine whether the applicant will have an SOP in place to describe the process that must be followed to confirm the loss or theft during transit.
- Confirm the identification of the person, within the organization, who will be responsible for receiving information regarding a loss or theft during transit.





Santé Canada Your health and safety our priority.

Votre santé et votre sécurité notre priorité.

- Confirm the identification of the person, within the organization, who will be responsible for investigating the loss or theft during transit with the shipping company.
- Confirm the identification of the person, within the organization, who will be responsible for advising the police and the Minister of the loss or theft during transit.

6.3.15 Destruction


- Confirm the applicant will have a process and/or system to handle and record the destruction of cannabis.
- If a destruction record template is available, assess whether all of the information will be captured as required under section 146 of the MMPR.

6.3.16 Adverse Reactions

- Confirm the applicant will have a process and/or system in place to record a
 case report for each serious adverse reaction to the dried marihuana they sell or
 provide.
- Confirm that the adverse reaction process includes a step to notify the Minister with each case report within 15 days after the day on which the applicant becomes aware of the reaction.
- Confirm that the adverse reaction process includes a step to prepare a summary report that will contain a concise and critical analysis of all adverse reactions to the dried marihuana that occurred during the previous 12 months.

6.3.17 Recall

- Confirm the applicant will have a process and/or system to address the recall of
 every lot or batch of dried marihuana that has been made available for sale (i.e.
 determining extent of the recall, and means of notifying affected parties).
- Confirm that the process and/or system includes a step to notify the Minister with the information required under section 62 of the MMPR within three days after the day on which the recall is commenced.
- Confirm the identification of the person(s), within the organization, who will be responsible for initiating and coordinating recall activities.
- Confirm the recall procedure can be put into operation at any time, during and outside normal working hours.





Santé Canada Your health and safety... our priority.

Votre santé et votre sécurité. notre priorité.

- Confirm the process and/or system the applicant intends to use to identify and store recalled products separately in a secure area until further action is determined.
- Confirm the applicant will assess and record at intervals the progress and efficacy of the recall, and will issue a final report, including a final reconciliation.
- Confirm the identification of the person, within the organization, who will be responsible for notifying all Canadian and foreign clients involved in the distribution and import of the recalled product.

6.3.17.1 Records

 Confirm the applicant will maintain distribution records so each lot can be traced.

6.3.18 Information Sharing

- Confirm the applicant will have a process and/or system in place to verify that
 the individual requesting information related to a possible client is a member of
 a Canadian police force.
- Confirm how the applicant intends to ensure that they respond within 72 hours after receiving the request from a member of a Canadian police force.

6.4 Exit interview

The exit interview will be conducted at the proposed licensed site after the prelicence inspection. Record the name and title of all individuals in attendance.

Findings, required changes, and improvements to the proposed security measures and internal controls should be discussed with the proposed designated personnel.

The proposed designated personnel should be informed that a copy of the inspection report will not be provided to the company.

The proposed designated personnel will also be informed that the results of the inspection will be shared with LPD and that LPD will make a decision about their application.



Santé Canada Your health and safety... our priority.

Votre santé et votre sécurité : notre priorité.

6.5 Writing of Report

Using the approved template (CS-FRM-0213 MMPR Pre-Licence Inspection Report) and guide (CS-FRM-0212 Guide to Completing the MMPR Pre-Licence Inspection Report), the Inspectors will write the inspection report. In the report, the Inspector will document the discrepancies which exist in terms of what has been observed versus what was provided in the application submission. Observations must be factual and must not include personal opinions, qualifiers or subjective comments. Observations must be formulated clearly, concisely and precisely aligned to the applicable regulatory requirement. Specific examples may be added for additional clarification.

The inspection report and related documents must not include any information pertaining to clients, individuals applying to become client applicants, or health care professionals, or any information that could potentially identify these individuals without prior discussion between the Lead Inspector and the RM. The RM will confirm if this information is required.

The Lead Inspector will make a general conclusion of the applicant's ability to comply with the MMPR.

The Lead Inspector will sign and date the pre-licence inspection report and submit it to the RM within five days. The RM will review the inspection report and sign it. The RM will scan and send the signed MMPR pre-licence inspection report to the Manager of the LPD and to the Manager of the NCED for administrative purposes.





Santé Canada Your health and safety. our priority.

Votre santé et votre sécurité ... notre priorité.

7. APPENDICES

CS-OF-001 Operational Framework for Compliance and Enforcement Activities for the Marihuana for Medical Purposes Regulations (MMPR)
CS-POL-001 CDSA Compliance and Enforcement Policy
CS-GD-010 MMPR Compliance Management and Endpoints

CS-FRM-0211 MMPR Pre-Licence Inspection Questionnaire

CS-FRM-0213 The MMPR Pre-Licence Inspection Report Template

CS-FRM-0212 Guide to Completing the MMPR Pre-Licence Inspection Report

8. REFERENCE DOCUMENTS

You may find it useful to refer to the following documents:

- CDSA
- MMPR
- Inspections reports and follow-up for other sites of the same company or group, if applicable

9. AUTHORS

The author of this document is: Jacqueline Oddi The editors of this document are:Denis Semail

Bonnie Falkenberg Miles Brosseau Ian Findlay Roy Thaller Courtney Smith

10. DOCUMENT REVISION HISTORY

| Version | Change Made | Effective Date |
|---------|-------------|--|
| | | |
| | | |
| | | The state of the s |
| | | |
| | | |
| | | |
| | | • |

